Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions

Abstract

Sarcopenia is defined as a muscle-wasting syndrome that occurs with accelerated aging, while cachexia is a severe wasting syndrome associated with conditions such as cancer and immunodeficiency disorders, which cannot be fully addressed through conventional nutritional supplementation. Sarcopenia can be considered a component of cachexia, with the bidirectional interplay between adipose tissue and skeletal muscle potentially serving as a molecular mechanism for both conditions. However, the underlying mechanisms differ. Recognizing the interplay and distinctions between these disorders is essential for advancing both basic and translational research in this area, enhancing diagnostic accuracy and ultimately achieving effective therapeutic solutions for affected patients. This review discusses the muscle microenvironment’s changes contributing to these conditions, recent therapeutic approaches like lifestyle modifications, small molecules, and nutritional interventions, and emerging strategies such as gene editing, stem cell therapy, and gut microbiome modulation. We also address the challenges and opportunities of multimodal interventions, aiming to provide insights into the pathogenesis and molecular mechanisms of sarcopenia and cachexia, ultimately aiding in innovative strategy development and improved treatments.

Keywords

cachexia / molecules / pathogenesis / sarcopenia / targeted therapy

References

[1] Rosenberg IH. Summary comments. Am J Clin Nutr. 1989; 50(5): 1231-1233.

[2] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(4): 601.

[3] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(1): 16-31.

[4] Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019; 393(10191): 2636-2646.

[5] Wiedmer P, Jung T, Castro JP, et al. Sarcopenia - Molecular mechanisms and open questions. Ageing Res Rev. 2021; 65: 101200.

[6] Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr. 2008; 27(6): 793-799.

[7] Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5): 489-495.

[8] Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. 2013; 4(3): 173-178.

[9] Ferrer M, Anthony TG, Ayres JS, et al. Cachexia: A systemic consequence of progressive, unresolved disease. Cell. 2023; 186(9): 1824-1845.

[10] Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr. 2010; 29(2): 154-159.

[11] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412-423.

[12] Setiawan T, Sari IN, Wijaya YT, et al. Cancer cachexia: molecular mechanisms and treatment strategies. J Hematol Oncol. 2023; 16(1): 54.

[13] Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr. 2007; 26(4): 389-399.

[14] Barreto SG. Pancreatic cancer: let us focus on cachexia, not just sarcopenia! Future Oncol. 2018; 14(27): 2791-2794.

[15] Vigano A, Kasvis P, Di Tomasso J, Gillis C, Kilgour R, Carli F. Pearls of optimizing nutrition and physical performance of older adults undergoing cancer therapy. J Geriatr Oncol. 2017; 8(6): 428-436.

[16] Compton SLE, Heymsfield SB, Brown JC. Nutritional mechanisms of cancer cachexia. Annu Rev Nutr. 2024; 44(1): 77-98.

[17] Cruz-Jentoft AJ, Landi F, Topinková E, Michel JP. Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care. 2010; 13(1): 1-7.

[18] Jensen GL. Inflammation: roles in aging and sarcopenia. JPEN J Parenter Enteral Nutr. 2008; 32(6): 656-659.

[19] Solheim TS, Laird BJA, Balstad TR, et al. Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support Palliat Care. 2018; 8(3): 258-265.

[20] Shen Y, Shi Q, Nong K, et al. Exercise for sarcopenia in older people: A systematic review and network meta-analysis. J Cachexia Sarcopenia Muscle. 2023; 14(3): 1199-1211.

[21] Lainscak M, Laviano A. ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker. J Cachexia Sarcopenia Muscle. 2016; 7(4): 400-402.

[22] Wang T, Zhou D, Hong Z. Adipose tissue in older individuals: a contributing factor to sarcopenia. Metabolism. 2024; 160: 155998.

[23] Shang M, Cappellesso F, Amorim R, et al. Macrophage-derived glutamine boosts satellite cells and muscle regeneration. Nature. 2020; 587(7835): 626-631.

[24] Yamakawa H, Kusumoto D, Hashimoto H, Yuasa S. Stem cell aging in skeletal muscle regeneration and disease. Inte J Mol Sci. 2020; 21(5): 101528.

[25] Sousa-Victor P, Muñoz-Cánoves P. Regenerative decline of stem cells in sarcopenia. Mol Aspects Med. 2016; 50: 109-117.

[26] Relaix F, Zammit PS. Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development. 2012; 139(16): 2845-2856.

[27] Sousa-Victor P, Gutarra S, García-Prat L, et al. Geriatric muscle stem cells switch reversible quiescence into senescence. Nature. 2014; 506(7488): 316-321.

[28] Fry CS, Lee JD, Mula J, et al. Inducible depletion of satellite cells in adult, sedentary mice impairs muscle regenerative capacity without affecting sarcopenia. Nat Med. 2015; 21(1): 76-80.

[29] Henze H, Jung MJ, Ahrens HE, Steiner S, von Maltzahn J. Skeletal muscle aging—stem cells in the spotlight. Mech Ageing Dev. 2020; 189: 111283.

[30] Hong X, Campanario S, Ramírez-Pardo I, Grima-Terrén M, Isern J, Muñoz-Cánoves P. Stem cell aging in the skeletal muscle: the importance of communication. Ageing Res Rev. 2022; 73: 101528.

[31] Hwang AB, Brack AS. Muscle stem cells and aging. Curr Top Dev Biol. 2018; 126: 299-322.

[32] Gibson MC, Schultz E. Age-related differences in absolute numbers of skeletal muscle satellite cells. Muscle Nerve. 1983; 6(8): 574-580.

[33] Shefer G, Van de Mark DP, Richardson JB, Yablonka-Reuveni Z. Satellite-cell pool size does matter: defining the myogenic potency of aging skeletal muscle. Dev Biol. 2006; 294(1): 50-66.

[34] Schultz E, Lipton BH. Skeletal muscle satellite cells: changes in proliferation potential as a function of age. Mech Ageing Dev. 1982; 20(4): 377-383.

[35] Taylor-Jones JM, McGehee RE, Rando TA, Lecka-Czernik B, Lipschitz DA, Peterson CA. Activation of an adipogenic program in adult myoblasts with age. Mech Ageing Dev. 2002; 123(6): 649-661.

[36] Brack AS, Conboy MJ, Roy S, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science. 2007; 317(5839): 807-810.

[37] Brzeszczyńska J, Meyer A, McGregor R, et al. Alterations in the in vitro and in vivo regulation of muscle regeneration in healthy ageing and the influence of sarcopenia. J Cachexia Sarcopenia Muscle. 2018; 9(1): 93-105.

[38] Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci. 2000; 908: 244-254.

[39] Hellerstein M, Evans W. Recent advances for measurement of protein synthesis rates, use of the ‘Virtual Biopsy’ approach, and measurement of muscle mass. Curr Opin Clin Nutr Metab Care. 2017; 20(3): 191-200.

[40] Philippou A, Halapas A, Maridaki M, Koutsilieris M. Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact. 2007; 7(3): 208-218.

[41] Bian A, Ma Y, Zhou X, et al. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. BMC Musculoskelet Disord. 2020; 21(1): 214.

[42] Zhang H, Liang J, Chen N. Do not neglect the role of circadian rhythm in muscle atrophy. Ageing Res Rev. 2020; 63: 101155.

[43] Livshits G, Kalinkovich A. Restoration of epigenetic impairment in the skeletal muscle and chronic inflammation resolution as a therapeutic approach in sarcopenia. Ageing Res Rev. 2024; 96: 102267.

[44] Liang Z, Zhang T, Liu H, et al. Inflammaging: The ground for sarcopenia? Exp Gerontol. 2022; 168: 111931.

[45] Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547): 1704-1708.

[46] Fulop T, Witkowski JM, Olivieri F, Larbi A. The integration of inflammaging in age-related diseases. Semin Immunol. 2018; 40: 17-35.

[47] Li J, Ayoub A, Xiu Y, et al. TGFβ-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosis. Nat Commun. 2019; 10(1): 2795.

[48] Feng M, Peng H, Yao R, et al. Inhibition of cellular communication network factor 1 (CCN1)-driven senescence slows down cartilage inflammaging and osteoarthritis. Bone. 2020; 139: 115522.

[49] Wang T. Searching for the link between inflammaging and sarcopenia. Ageing Res Rev. 2022; 77: 101611.

[50] Liang Z, Zhang T, Liu H, et al. Inflammaging: The ground for sarcopenia? Exp Gerontol. 2022; 168: 111931.

[51] Wang T, He C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018; 44: 38-50.

[52] Wang T, He C. TNF-α and IL-6: the link between immune and bone system. Curr Drug Targets. 2020; 21(3): 213-227.

[53] Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019; 25(12): 1822-1832.

[54] Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007; 128(1): 92-105.

[55] Franceschi C, Garagnani P, Morsiani C, et al. The continuum of aging and age-related diseases: common mechanisms but different rates. Front Med (Lausanne). 2018; 5: 61.

[56] Wilson D, Jackson T, Sapey E, Lord JM. Frailty and sarcopenia: the potential role of an aged immune system. Ageing Res Rev. 2017; 36: 1-10.

[57] Perretti M, D’Acquisto F. Novel aspects of annexin 1 and glucocorticoid biology: intersection with nitric oxide and the lipoxin receptor. Inflamm Allergy Drug Targets. 2006; 5(2): 107-114.

[58] Pan L, Xie W, Fu X, et al. Inflammation and sarcopenia: A focus on circulating inflammatory cytokines. Exp Gerontol. 2021; 154: 111544.

[59] Sullivan-Gunn MJ, Lewandowski PA. Elevated hydrogen peroxide and decreased catalase and glutathione peroxidase protection are associated with aging sarcopenia. BMC Geriatr. 2013; 13: 104.

[60] Zembroń-Łacny A, Dziubek W, Rogowski Ł, Skorupka E, Dąbrowska G. Sarcopenia: monitoring, molecular mechanisms, and physical intervention. Physiol Res. 2014; 63(6): 683-691.

[61] McCormick R, Vasilaki A. Age-related changes in skeletal muscle: changes to life-style as a therapy. Biogerontology. 2018; 19(6): 519-536.

[62] Chabi B, Ljubicic V, Menzies KJ, Huang JH, Saleem A, Hood DA. Mitochondrial function and apoptotic susceptibility in aging skeletal muscle. Aging Cell. 2008; 7(1): 2-12.

[63] Feng LT, Chen ZN, Bian H. Skeletal muscle: molecular structure, myogenesis, biological functions, and diseases. MedComm. 2024; 5(7): e649.

[64] Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010; 95(4): 1810-1818.

[65] Perry HM, 3rd, Miller DK, Patrick P, Morley JE. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism. 2000; 49(8): 1085-1091.

[66] Galvão DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008; 102(1): 44-47.

[67] Xu Y, Deng KL, Xing TF, Mei YQ, Xiao SM. Effect of hormone therapy on muscle strength in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2020; 27(7): 827-835.

[68] Javed AA, Mayhew AJ, Shea AK, Raina P. Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019; 2(8): e1910154.

[69] Rolland Y, Dray C, Vellas B, Barreto PS. Current and investigational medications for the treatment of sarcopenia. Metabolism. 2023; 149: 155597.

[70] Merz KE, Thurmond DC. Role of skeletal muscle in insulin resistance and glucose uptake. Compr Physiol. 2020; 10(3): 785-809.

[71] Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018; 98(4): 2133-2223.

[72] Dyar KA, Ciciliot S, Wright LE, et al. Muscle insulin sensitivity and glucose metabolism are controlled by the intrinsic muscle clock. Mol Metab. 2014; 3(1): 29-41.

[73] Harfmann BD, Schroder EA, Kachman MT, Hodge BA, Zhang X, Esser KA. Muscle-specific loss of Bmal1 leads to disrupted tissue glucose metabolism and systemic glucose homeostasis. Skelet Muscle. 2016; 6: 12.

[74] Schiaffino S, Blaauw B, Dyar KA. The functional significance of the skeletal muscle clock: lessons from Bmal1 knockout models. Skelet Muscle. 2016; 6: 33.

[75] Verma S, Khurana S, Vats A, et al. Neuromuscular junction dysfunction in amyotrophic lateral sclerosis. Mol Neurobiol. 2022; 59(3): 1502-1527.

[76] Fish LA, Fallon JR. Multiple MuSK signaling pathways and the aging neuromuscular junction. Neurosci Lett. 2020; 731: 135014.

[77] Lovering RM, Iyer SR, Edwards B, Davies KE. Alterations of neuromuscular junctions in Duchenne muscular dystrophy. Neurosci Lett. 2020; 737: 135304.

[78] Kalinkovich A, Livshits G. Sarcopenia–The search for emerging biomarkers. Ageing Res Rev. 2015; 22: 58-71.

[79] Courtney J, Steinbach JH. Age changes in neuromuscular junction morphology and acetylcholine receptor distribution on rat skeletal muscle fibres. J Physiol. 1981; 320: 435-447.

[80] Smith DO, Chapman MR. Acetylcholine receptor binding properties at the rat neuromuscular junction during aging. J Neurochem. 1987; 48(6): 1834-1841.

[81] Li CW, Yu K, Shyh-Chang N, et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. J Cachexia Sarcopenia Muscle. 2022; 13(2): 781-794.

[82] Katzir I, Adler M, Karin O, Mendelsohn-Cohen N, Mayo A, Alon U. Senescent cells and the incidence of age-related diseases. Aging Cell. 2021; 20(3): e13314.

[83] Sikora E, Bielak-Zmijewska A, Mosieniak G. Targeting normal and cancer senescent cells as a strategy of senotherapy. Ageing Res Rev. 2019; 55: 100941.

[84] Wang T, Huang S, He C. Senescent cells: a therapeutic target for osteoporosis. Cell Prolif. 2022; 55(12): e13323.

[85] Shakeri H, Lemmens K, Gevaert AB, De Meyer GRY, Segers VFM. Cellular senescence links aging and diabetes in cardiovascular disease. Am J Physiol Heart Circ Physiol. 2018; 315(3): H448-H462.

[86] Nelson G, Wordsworth J, Wang C, et al. A senescent cell bystander effect: senescence-induced senescence. Aging Cell. 2012; 11(2): 345-349.

[87] Jejurikar SS, Henkelman EA, Cederna PS, Marcelo CL, Urbanchek MG, Kuzon WM, Jr. Aging increases the susceptibility of skeletal muscle derived satellite cells to apoptosis. Exp Gerontol. 2006; 41(9): 828-836.

[88] Zhang X, Habiballa L, Aversa Z, et al. Characterization of cellular senescence in aging skeletal muscle. Nat Aging. 2022; 2(7): 601-615.

[89] Rathbone CR, Booth FW, Lees SJ. Sirt1 increases skeletal muscle precursor cell proliferation. Eur J Cell Biol. 2009; 88(1): 35-44.

[90] Alway SE, McCrory JL, Kearcher K, et al. Resveratrol enhances exercise-induced cellular and functional adaptations of skeletal muscle in older men and women. J Gerontol A Biol Sci Med Sci. 2017; 72(12): 1595-1606.

[91] Saini A, Al-Shanti N, Sharples AP, Stewart CE. Sirtuin 1 regulates skeletal myoblast survival and enhances differentiation in the presence of resveratrol. Exp Physiol. 2012; 97(3): 400-418.

[92] Ou MY, Zhang H, Tan PC, Zhou SB, Li QF. Adipose tissue aging: mechanisms and therapeutic implications. Cell Death Dis. 2022; 13(4): 300.

[93] Ferhat M, Funai K, Boudina S. Autophagy in Adipose Tissue Physiology and Pathophysiology. Antioxid Redox Signal. 2019; 31(6): 487-501.

[94] Wang W, Seale P. Control of brown and beige fat development. Nat Rev Mol Cell Biol. 2016; 17(11): 691-702.

[95] Goodpaster BH, Carlson CL, Visser M, et al. Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. J Appl Physiol (1985). 2001; 90(6): 2157-2165.

[96] Visser M, Kritchevsky SB, Goodpaster BH, et al. Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study. J Am Geriatr Soc. 2002; 50(5): 897-904.

[97] JafariNasabian P, Inglis JE, Reilly W, Kelly OJ, Ilich JZ. Aging human body: changes in bone, muscle and body fat with consequent changes in nutrient intake. J Endocrinol. 2017; 234(1): R37-R51.

[98] Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev. 2017; 35: 200-221.

[99] Addison O, Drummond MJ, LaStayo PC, et al. Intramuscular fat and inflammation differ in older adults: the impact of frailty and inactivity. J Nutr Health Aging. 2014; 18(5): 532-538.

[100] Delmonico MJ, Harris TB, Visser M, et al. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr. 2009; 90(6): 1579-1585.

[101] Chen Y, Hu Q, Wang C, Wang T. The crosstalk between BAT thermogenesis and skeletal muscle dysfunction. Front Physiol. 2023; 14: 1132830.

[102] Montanari T, Pošćić N, Colitti M. Factors involved in white-to-brown adipose tissue conversion and in thermogenesis: a review. Obes Rev. 2017; 18(5): 495-513.

[103] Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009; 360(15): 1518-1525.

[104] Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004; 84(1): 277-359.

[105] Liu X, Zheng Z, Zhu X, et al. Brown adipose tissue transplantation improves whole-body energy metabolism. Cell Res. 2013; 23(6): 851-854.

[106] Yuan X, Hu T, Zhao H, et al. Brown adipose tissue transplantation ameliorates polycystic ovary syndrome. Proc Natl Acad Sci USA. 2016; 113(10): 2708-2713.

[107] O’Mara AE, Johnson JW, Linderman JD, et al. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. J Clin Invest. 2020; 130(5): 2209-2219.

[108] Orava J, Nuutila P, Lidell ME, et al. Different metabolic responses of human brown adipose tissue to activation by cold and insulin. Cell Metab. 2011; 14(2): 272-279.

[109] Sanchez-Gurmaches J, Hung CM, Sparks CA, Tang Y, Li H, Guertin DA. PTEN loss in the Myf5 lineage redistributes body fat and reveals subsets of white adipocytes that arise from Myf5 precursors. Cell Metab. 2012; 16(3): 348-362.

[110] Seale P, Bjork B, Yang W, et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature. 2008; 454(7207): 961-967.

[111] Zoico E, Rubele S, De Caro A, et al. Brown and beige adipose tissue and aging. Front Endocrinol (Lausanne). 2019; 10: 368.

[112] Ouellet V, Routhier-Labadie A, Bellemare W, et al. Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of 18F-FDG-detected BAT in humans. J Clin Endocrinol Metab. 2011; 96(1): 192-199.

[113] Valle A, Santandreu FM, García-Palmer FJ, Roca P, Oliver J. The serum levels of 17beta-estradiol, progesterone and triiodothyronine correlate with brown adipose tissue thermogenic parameters during aging. Cell Physiol Biochem. 2008; 22(1-4): 337-346.

[114] Wagner JA, Horvath SM. Influences of age and gender on human thermoregulatory responses to cold exposures. J Appl Physiol (1985). 1985; 58(1): 180-186.

[115] Villarroya J, Cereijo R, Gavaldà-Navarro A, Peyrou M, Giralt M, Villarroya F. New insights into the secretory functions of brown adipose tissue. J Endocrinol. 2019; 243(2): R19-R27.

[116] Villarroya J, Cereijo R, Villarroya F. An endocrine role for brown adipose tissue? Am J Physiol Endocrinol Metab. 2013; 305(5): E567-E572.

[117] Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med. 2013; 34(1): 1-11.

[118] Von Bank H, Kirsh C, Simcox J. Aging adipose: depot location dictates age-associated expansion and dysfunction. Ageing Res Rev. 2021; 67: 101259.

[119] Karpe F, Pinnick KE. Biology of upper-body and lower-body adipose tissue–link to whole-body phenotypes. Nat Rev Endocrinol. 2015; 11(2): 90-100.

[120] Viljanen AP, Lautamäki R, Järvisalo M, et al. Effects of weight loss on visceral and abdominal subcutaneous adipose tissue blood-flow and insulin-mediated glucose uptake in healthy obese subjects. Ann Med. 2009; 41(2): 152-160.

[121] Abildgaard J, Ploug T, Al-Saoudi E, et al. Changes in abdominal subcutaneous adipose tissue phenotype following menopause is associated with increased visceral fat mass. Sci Rep. 2021; 11(1): 14750.

[122] Jeffery E, Wing A, Holtrup B, et al. The adipose tissue microenvironment regulates depot-specific adipogenesis in obesity. Cell Metab. 2016; 24(1): 142-150.

[123] Choi WG, Choi W, Oh TJ, et al. Inhibiting serotonin signaling through HTR2B in visceral adipose tissue improves obesity-related insulin resistance. J Clin Invest. 2021; 131(23): e145331.

[124] Vishvanath L, Gupta RK. Contribution of adipogenesis to healthy adipose tissue expansion in obesity. J Clin Invest. 2019; 129(10): 4022-4031.

[125] Schipper BM, Marra KG, Zhang W, Donnenberg AD, Rubin JP. Regional anatomic and age effects on cell function of human adipose-derived stem cells. Ann Plast Surg. 2008; 60(5): 538-544.

[126] Kim SM, Lun M, Wang M, et al. Loss of white adipose hyperplastic potential is associated with enhanced susceptibility to insulin resistance. Cell Metab. 2014; 20(6): 1049-1058.

[127] Guo W, Pirtskhalava T, Tchkonia T, et al. Aging results in paradoxical susceptibility of fat cell progenitors to lipotoxicity. Am J Physiol Endocrinol Metab. 2007; 292(4): E1041-E1051.

[128] Kirkland JL, Hollenberg CH, Gillon WS. Age, anatomic site, and the replication and differentiation of adipocyte precursors. Am J Physiol. 1990; 258(2 Pt 1): C206-C210.

[129] Karagiannides I, Tchkonia T, Dobson DE, et al. Altered expression of C/EBP family members results in decreased adipogenesis with aging. Am J Physiol Regul Integr Comp Physiol. 2001; 280(6): R1772-R1780.

[130] Tchkonia T, Morbeck DE, Von Zglinicki T, et al. Fat tissue, aging, and cellular senescence. Aging Cell. 2010; 9(5): 667-684.

[131] Stout MB, Tchkonia T, Pirtskhalava T, et al. Growth hormone action predicts age-related white adipose tissue dysfunction and senescent cell burden in mice. Aging (Albany NY). 2014; 6(7): 575-586.

[132] Xu M, Palmer AK, Ding H, et al. Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife. 2015; 4: e12997.

[133] Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019; 47: 446-456.

[134] Khan S, Chan YT, Revelo XS, Winer DA. The immune landscape of visceral adipose tissue during obesity and aging. Front Endocrinol (Lausanne). 2020; 11: 267.

[135] Lumeng CN, Liu J, Geletka L, et al. Aging is associated with an increase in T cells and inflammatory macrophages in visceral adipose tissue. J Immunol. 2011; 187(12): 6208-6216.

[136] Arai Y, Takayama M, Abe Y, Hirose N. Adipokines and aging. J Atheroscler Thromb. 2011; 18(7): 545-550.

[137] Chen W, You W, Valencak TG, Shan T. Bidirectional roles of skeletal muscle fibro-adipogenic progenitors in homeostasis and disease. Ageing research reviews. 2022; 80: 101682.

[138] Henin G, Loumaye A, Leclercq IA, Lanthier N. Myosteatosis: diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease. JHEP Rep. 2023; 6: 100963.

[139] Uezumi A, Ikemoto-Uezumi M, Zhou H, et al. Mesenchymal Bmp3b expression maintains skeletal muscle integrity and decreases in age-related sarcopenia. J Clin Invest. 2021; 131(1): e139617.

[140] Lukjanenko L, Karaz S, Stuelsatz P, et al. Aging disrupts muscle stem cell function by impairing matricellular WISP1 secretion from fibro-adipogenic progenitors. Cell Stem Cell. 2019; 24(3): 433-446. e7.

[141] Kang X, Yang MY, Shi YX, et al. Interleukin-15 facilitates muscle regeneration through modulation of fibro/adipogenic progenitors. Cell Commun Signal. 2018; 16(1): 42.

[142] Molina T, Fabre P, Dumont NA. Fibro-adipogenic progenitors in skeletal muscle homeostasis, regeneration and diseases. Open Biol. 2021; 11(12): 210110.

[143] Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018; 24(8): 1246-1256.

[144] Joe AW, Yi L, Natarajan A, et al. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol. 2010; 12(2): 153-163.

[145] Lemos DR, Babaeijandaghi F, Low M, et al. Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat Med. 2015; 21(7): 786-794.

[146] Kuswanto W, Burzyn D, Panduro M, et al. Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory T cells. Immunity. 2016; 44(2): 355-367.

[147] Moratal C, Arrighi N, Dechesne CA, Dani C. Control of muscle fibro-adipogenic progenitors by myogenic lineage is altered in aging and duchenne muscular dystrophy. Cell Physiol Biochem. 2019; 53(6): 1029-1045.

[148] Murphy MM, Lawson JA, Mathew SJ, Hutcheson DA, Kardon G. Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. Development. 2011; 138(17): 3625-3637.

[149] Hogarth MW, Defour A, Lazarski C, et al. Fibroadipogenic progenitors are responsible for muscle loss in limb girdle muscular dystrophy 2B. Nat Commun. 2019; 10(1): 2430.

[150] Marinkovic M, Fuoco C, Sacco F, et al. Fibro-adipogenic progenitors of dystrophic mice are insensitive to NOTCH regulation of adipogenesis. Life Sci Alliance. 2019; 2(3): e201900437.

[151] Vertino AM, Taylor-Jones JM, Longo KA, et al. Wnt10b deficiency promotes coexpression of myogenic and adipogenic programs in myoblasts. Mol Biol Cell. 2005; 16(4): 2039-2048.

[152] Cordani N, Pisa V, Pozzi L, Sciorati C, Clementi E. Nitric oxide controls fat deposition in dystrophic skeletal muscle by regulating fibro-adipogenic precursor differentiation. Stem Cells. 2014; 32(4): 874-885.

[153] Samengo G, Avik A, Fedor B, et al. Age-related loss of nitric oxide synthase in skeletal muscle causes reductions in calpain S-nitrosylation that increase myofibril degradation and sarcopenia. Aging Cell. 2012; 11(6): 1036-1045.

[154] Buras ED, Converso-Baran K, Davis CS, et al. Fibro-adipogenic remodeling of the diaphragm in obesity-associated respiratory dysfunction. Diabetes. 2019; 68(1): 45-56.

[155] Laurens C, Louche K, Sengenes C, et al. Adipogenic progenitors from obese human skeletal muscle give rise to functional white adipocytes that contribute to insulin resistance. Int J Obes (Lond). 2016; 40(3): 497-506.

[156] Arrighi N, Moratal C, Clément N, et al. Characterization of adipocytes derived from fibro/adipogenic progenitors resident in human skeletal muscle. Cell Death Dis. 2015; 6(4): e1733.

[157] Kong P, Gonzalez-Quesada C, Li N, Cavalera M, Lee DW, Frangogiannis NG. Thrombospondin-1 regulates adiposity and metabolic dysfunction in diet-induced obesity enhancing adipose inflammation and stimulating adipocyte proliferation. Am J Physiol Endocrinol Metab. 2013; 305(3): E439-E450.

[158] Mogi M, Kohara K, Nakaoka H, et al. Diabetic mice exhibited a peculiar alteration in body composition with exaggerated ectopic fat deposition after muscle injury due to anomalous cell differentiation. J Cachexia Sarcopenia Muscle. 2016; 7(2): 213-224.

[159] Miljkovic-Gacic I, Gordon CL, Goodpaster BH, et al. Adipose tissue infiltration in skeletal muscle: age patterns and association with diabetes among men of African ancestry. Am J Clin Nutr. 2008; 87(6): 1590-1595.

[160] Visser M, Goodpaster BH, Kritchevsky SB, et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci. 2005; 60(3): 324-333.

[161] Akazawa N, Kishi M, Hino T, et al. Intramuscular adipose tissue in the quadriceps is more strongly related to recovery of activities of daily living than muscle mass in older inpatients. J Cachexia Sarcopenia Muscle. 2021; 12(4): 891-899.

[162] Hilton TN, Tuttle LJ, Bohnert KL, Mueller MJ, Sinacore DR. Excessive adipose tissue infiltration in skeletal muscle in individuals with obesity, diabetes mellitus, and peripheral neuropathy: association with performance and function. Phys Ther. 2008; 88(11): 1336-1344.

[163] Song MY, Ruts E, Kim J, Janumala I, Heymsfield S, Gallagher D. Sarcopenia and increased adipose tissue infiltration of muscle in elderly African American women. Am J Clin Nutr. 2004; 79(5): 874-880.

[164] Boettcher M, Machann J, Stefan N, et al. Intermuscular adipose tissue (IMAT): association with other adipose tissue compartments and insulin sensitivity. J Magn Reson Imaging. 2009; 29(6): 1340-1345.

[165] Yim JE, Heshka S, Albu J, et al. Intermuscular adipose tissue rivals visceral adipose tissue in independent associations with cardiovascular risk. Int J Obes (2005). 2007; 31(9): 1400-1405.

[166] Beasley LE, Koster A, Newman AB, et al. Inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity (Silver Spring). 2009; 17(5): 1062-1069.

[167] Manini TM, Clark BC, Nalls MA, Goodpaster BH, Ploutz-Snyder LL, Harris TB. Reduced physical activity increases intermuscular adipose tissue in healthy young adults. Am J Clin Nutr. 2007; 85(2): 377-384.

[168] Pagano AF, Brioche T, Arc-Chagnaud C, Demangel R, Chopard A, Py G. Short-term disuse promotes fatty acid infiltration into skeletal muscle. J Cachexia Sarcopenia Muscle. 2018; 9(2): 335-347.

[169] St-Jean-Pelletier F, Pion CH, Leduc-Gaudet JP, et al. The impact of ageing, physical activity, and pre-frailty on skeletal muscle phenotype, mitochondrial content, and intramyocellular lipids in men. J Cachexia Sarcopenia Muscle. 2017; 8(2): 213-228.

[170] Ryan AS, Buscemi A, Forrester L, Hafer-Macko CE, Ivey FM. Atrophy and intramuscular fat in specific muscles of the thigh: associated weakness and hyperinsulinemia in stroke survivors. Neurorehabil Neural Repair. 2011; 25(9): 865-872.

[171] Tuttle LJ, Sinacore DR, Cade WT, Mueller MJ. Lower physical activity is associated with higher intermuscular adipose tissue in people with type 2 diabetes and peripheral neuropathy. Phys Ther. 2011; 91(6): 923-930.

[172] Addison O, Marcus RL, Lastayo PC, Ryan AS. Intermuscular fat: a review of the consequences and causes. Int J Endocrinol. 2014; 2014: 309570.

[173] Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab. 2006; 290(5): E961-E967.

[174] Lambert CP, Wright NR, Finck BN, Villareal DT. Exercise but not diet-induced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons. J Appl Physiol (1985). 2008; 105(2): 473-478.

[175] Marcus RL, Addison O, Kidde JP, Dibble LE, Lastayo PC. Skeletal muscle fat infiltration: impact of age, inactivity, and exercise. J Nutr Health Aging. 2010; 14(5): 362-366.

[176] de Almeida AC, Aily JB, Pedroso MG, et al. A periodized training attenuates thigh intermuscular fat and improves muscle quality in patients with knee osteoarthritis: results from a randomized controlled trial. Clin Rheumatol. 2020; 39(4): 1265-1275.

[177] Wroblewski AP, Amati F, Smiley MA, Goodpaster B, Wright V. Chronic exercise preserves lean muscle mass in masters athletes. Phys Sportsmed. 2011; 39(3): 172-178.

[178] Choi SJ, Files DC, Zhang T, et al. Intramyocellular lipid and impaired myofiber contraction in normal weight and obese older adults. J Gerontol A Biol Sci Med Sci. 2016; 71(4): 557-564.

[179] Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab. 2001; 86(12): 5755-5761.

[180] Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol. 2016; 229(2): R67-R81.

[181] Aon MA, Bhatt N, Cortassa SC. Mitochondrial and cellular mechanisms for managing lipid excess. Front Physiol. 2014; 5: 282.

[182] Broskey NT, Obanda DN, Burton JH, Cefalu WT, Ravussin E. Skeletal muscle ceramides and daily fat oxidation in obesity and diabetes. Metabolism. 2018; 82: 118-123.

[183] Di Meo S, Iossa S, Venditti P. Skeletal muscle insulin resistance: role of mitochondria and other ROS sources. J Endocrinol. 2017; 233(1): R15-R42.

[184] Wu H, Ballantyne CM. Skeletal muscle inflammation and insulin resistance in obesity. J Clin Invest. 2017; 127(1): 43-54.

[185] Rivas DA, McDonald DJ, Rice NP, Haran PH, Dolnikowski GG, Fielding RA. Diminished anabolic signaling response to insulin induced by intramuscular lipid accumulation is associated with inflammation in aging but not obesity. Am J Physiol Regul Integr Comp Physiol. 2016; 310(7): R561-R569.

[186] Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol. 2016; 12(1): 15-28.

[187] Krajnak K, Waugh S, Miller R, et al. Proapoptotic factor Bax is increased in satellite cells in the tibialis anterior muscles of old rats. Muscle Nerve. 2006; 34(6): 720-730.

[188] Przybyla B, Gurley C, Harvey JF, et al. Aging alters macrophage properties in human skeletal muscle both at rest and in response to acute resistance exercise. Exp Gerontol. 2006; 41(3): 320-327.

[189] Wang Y, Wehling-Henricks M, Welc SS, Fisher AL, Zuo Q, Tidball JG. Aging of the immune system causes reductions in muscle stem cell populations, promotes their shift to a fibrogenic phenotype, and modulates sarcopenia. FASEB J. 2019; 33(1): 1415-1427.

[190] Franco C, Gatto M, Iaccarino L, Ghirardello A, Doria A. Lymphocyte immunophenotyping in inflammatory myositis: a review. Curr Opin Rheumatol. 2021; 33(6): 522-528.

[191] Zhang J, Xiao Z, Qu C, Cui W, Wang X, Du J. CD8 T cells are involved in skeletal muscle regeneration through facilitating MCP-1 secretion and Gr1(high) macrophage infiltration. J Immunol. 2014; 193(10): 5149-5160.

[192] Huang SW, Xu T, Zhang CT, Zhou HL. Relationship of Peripheral Lymphocyte Subsets and Skeletal Muscle Mass Index in Sarcopenia: A Cross-Sectional Study. J Nutr Health Aging. 2020; 24(3): 325-329.

[193] Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol. 2003; 3(12): 939-951.

[194] Weyand CM, Brandes JC, Schmidt D, Fulbright JW, Goronzy JJ. Functional properties of CD4+ CD28-T cells in the aging immune system. Mech Ageing Dev. 1998; 102(2-3): 131-147.

[195] Al-Dabbagh S, McPhee JS, Murgatroyd C, Butler-Browne G, Stewart CE, Al-Shanti N. The lymphocyte secretome from young adults enhances skeletal muscle proliferation and migration, but effects are attenuated in the secretome of older adults. Physiol Rep. 2015; 3(11): e12518.

[196] Dumke BR, Lees SJ. Age-related impairment of T cell-induced skeletal muscle precursor cell function. Am J Physiol Cell Physiol. 2011; 300(6): C1226-C1233.

[197] Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30: 531-564.

[198] Villalta SA, Rosenthal W, Martinez L, et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med. 2014;6(258):258ra142.

[199] Saclier M, Yacoub-Youssef H, Mackey AL, et al. Differentially activated macrophages orchestrate myogenic precursor cell fate during human skeletal muscle regeneration. Stem Cells. 2013; 31(2): 384-396.

[200] Brunelli S, Rovere-Querini P. The immune system and the repair of skeletal muscle. Pharmacol Res. 2008; 58(2): 117-121.

[201] Villalta SA, Deng B, Rinaldi C, Wehling-Henricks M, Tidball JG. IFN-γ promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation. J Immunol. 2011; 187(10): 5419-5428.

[202] Perdiguero E, Sousa-Victor P, Ruiz-Bonilla V, et al. p38/MKP-1-regulated AKT coordinates macrophage transitions and resolution of inflammation during tissue repair. J Cell Biol. 2011; 195(2): 307-322.

[203] Wang Y, Wehling-Henricks M, Samengo G, Tidball JG. Increases of M2a macrophages and fibrosis in aging muscle are influenced by bone marrow aging and negatively regulated by muscle-derived nitric oxide. Aging Cell. 2015; 14(4): 678-688.

[204] Hearps AC, Martin GE, Angelovich TA, et al. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell. 2012; 11(5): 867-875.

[205] Nyugen J, Agrawal S, Gollapudi S, Gupta S. Impaired functions of peripheral blood monocyte subpopulations in aged humans. J Clin Immunol. 2010; 30(6): 806-813.

[206] Qian F, Wang X, Zhang L, et al. Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly. Aging Cell. 2012; 11(1): 104-110.

[207] Barazzoni R, Bischoff SC, Boirie Y, et al. Sarcopenic obesity: Time to meet the challenge. Clin Nutr. 2018; 37(6 Pt A): 1787-1793.

[208] Pellegrinelli V, Rouault C, Rodriguez-Cuenca S, et al. Human adipocytes induce inflammation and atrophy in muscle cells during obesity. Diabetes. 2015; 64(9): 3121-3134.

[209] Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Investig. 2017; 127(1): 1-4.

[210] Dam V, Sikder T, Santosa S. From neutrophils to macrophages: differences in regional adipose tissue depots. Obes Rev. 2016; 17(1): 1-17.

[211] Mraz M, Haluzik M. The role of adipose tissue immune cells in obesity and low-grade inflammation. J Endocrinol. 2014; 222(3): R113-R127.

[212] Vieira-Potter VJ. Inflammation and macrophage modulation in adipose tissues. Cell Microbiol. 2014; 16(10): 1484-1492.

[213] Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005; 46(11): 2347-2355.

[214] Murano I, Barbatelli G, Parisani V, et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res. 2008; 49(7): 1562-1568.

[215] Apovian CM, Bigornia S, Mott M, et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol. 2008; 28(9): 1654-1659.

[216] Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA. 2003; 100(12): 7265-7270.

[217] Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med. 2004; 36(2): 98-118.

[218] Saberi M, Woods NB, de Luca C, et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab. 2009; 10(5): 419-429.

[219] Jiao P, Chen Q, Shah S, et al. Obesity-related upregulation of monocyte chemotactic factors in adipocytes: involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways. Diabetes. 2009; 58(1): 104-115.

[220] Winer S, Chan Y, Paltser G, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009; 15(8): 921-929.

[221] Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009; 15(8): 930-939.

[222] Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009; 15(8): 914-920.

[223] Winer DA, Winer S, Shen L, et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med. 2011; 17(5): 610-617.

[224] Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest. 1996; 97(4): 1111-1116.

[225] Moratal C, Raffort J, Arrighi N, et al. IL-1β-and IL-4-polarized macrophages have opposite effects on adipogenesis of intramuscular fibro-adipogenic progenitors in humans. Sci Rep. 2018; 8(1): 17005.

[226] Boon MR, Bakker LE, Haks MC, et al. Short-term high-fat diet increases macrophage markers in skeletal muscle accompanied by impaired insulin signalling in healthy male subjects. Clin Sci (Lond). 2015; 128(2): 143-151.

[227] Tam CS, Covington JD, Bajpeyi S, et al. Weight gain reveals dramatic increases in skeletal muscle extracellular matrix remodeling. J Clin Endocrinol Metab. 2014; 99(5): 1749-1757.

[228] Khan IM, Perrard XY, Brunner G, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes (Lond). 2015; 39(11): 1607-1618.

[229] Fink LN, Costford SR, Lee YS, et al. Pro-inflammatory macrophages increase in skeletal muscle of high fat-fed mice and correlate with metabolic risk markers in humans. Obesity (Silver Spring). 2014; 22(3): 747-757.

[230] Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol. 2005; 25(10): 2062-2068.

[231] Wu H, Ghosh S, Perrard XD, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation. 2007; 115(8): 1029-1038.

[232] Patsouris D, Cao JJ, Vial G, et al. Insulin resistance is associated with MCP1-mediated macrophage accumulation in skeletal muscle in mice and humans. PLoS One. 2014; 9(10): e110653.

[233] DeJong CH, Busquets S, Moses AG, et al. Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol Rep. 2005; 14(1): 257-263.

[234] Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 2002; 87(3): 264-267.

[235] Wang YF, An ZY, Lin DH, Jin WL. Targeting cancer cachexia: Molecular mechanisms and clinical study. MedComm. 2022; 3(4): e164.

[236] Torti FM, Dieckmann B, Beutler B, Cerami A, Ringold GM. A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science. 1985; 229(4716): 867-869.

[237] Cerami A, Ikeda Y, Le Trang N, Hotez PJ, Beutler B. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett. 1985; 11(3-4): 173-177.

[238] Peixoto da Silva S, Santos JMO, Costa ESMP, Gil da Costa RM, Medeiros R. Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia. J Cachexia Sarcopenia Muscle. 2020; 11(3): 619-635.

[239] Onesti JK, Guttridge DC. Inflammation based regulation of cancer cachexia. Biomed Res Int. 2014; 2014: 168407.

[240] Mantovani G, Macciò A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med (Berl). 2000; 78(10): 554-561.

[241] Argilés JM, Busquets S, López-Soriano FJ. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care. 2003; 6(4): 401-406.

[242] Porporato PE. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 2016; 5(2): e200.

[243] Albrecht JT, Canada TW. Cachexia and anorexia in malignancy. Hematol Oncol Clin North Am. 1996; 10(4): 791-800.

[244] Acharyya S, Ladner KJ, Nelsen LL, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest. 2004; 114(3): 370-378.

[245] Petruzzelli M, Schweiger M, Schreiber R, et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 2014; 20(3): 433-447.

[246] Kitajima Y, Yoshioka K, Suzuki N. The ubiquitin-proteasome system in regulation of the skeletal muscle homeostasis and atrophy: from basic science to disorders. J Physiol Sci. 2020; 70(1): 40.

[247] Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr. 1999; 129(1S Suppl): 227s-237s.

[248] Tisdale MJ. Molecular pathways leading to cancer cachexia. Physiology (Bethesda). 2005; 20: 340-348.

[249] Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014; 14(11): 754-762.

[250] Fanzani A, Conraads VM, Penna F, Martinet W. Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle. 2012; 3(3): 163-179.

[251] Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2010; 1(1): 9-21.

[252] Williams A, Sun X, Fischer JE, Hasselgren PO. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 1999; 126(4): 744-749; discussion 749–50.

[253] Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg. 2003; 237(3): 384-389.

[254] Du J, Wang X, Miereles C, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest. 2004; 113(1): 115-123.

[255] Yang W, Huang J, Wu H, et al. Molecular mechanisms of cancer cachexia-induced muscle atrophy (Review). Mol Med Rep. 2020; 22(6): 4967-4980.

[256] Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2015; 6(3): 197-207.

[257] Boyer-Guittaut M, Poillet L, Liang Q, et al. The role of GABARAPL1/GEC1 in autophagic flux and mitochondrial quality control in MDA-MB-436 breast cancer cells. Autophagy. 2014; 10(6): 986-1003.

[258] Tardif N, Klaude M, Lundell L, Thorell A, Rooyackers O. Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am J Clin Nutr. 2013; 98(6): 1485-1492.

[259] de Castro GS, Simoes E, Lima J, et al. Human cachexia induces changes in mitochondria, autophagy and apoptosis in the skeletal muscle. Cancers (Basel). 2019; 11(9): 1264.

[260] Op den Kamp CM, Langen RC, Snepvangers FJ, et al. Nuclear transcription factor κ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr. 2013; 98(3): 738-748.

[261] Aversa Z, Pin F, Lucia S, et al. Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci Rep. 2016; 6: 30340.

[262] Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS, Jr. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000; 289(5488): 2363-2366.

[263] Ma JF, Sanchez BJ, Hall DT, Tremblay AK, Di Marco S, Gallouzi IE. STAT3 promotes IFNγ/TNFα-induced muscle wasting in an NF-κB-dependent and IL-6-independent manner. EMBO Mol Med. 2017; 9(5): 622-637.

[264] Mueller TC, Bachmann J, Prokopchuk O, Friess H, Martignoni ME. Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia–can findings from animal models be translated to humans? BMC Cancer. 2016; 16: 75.

[265] Martin A, Gallot YS, Freyssenet D. Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies. J Cachexia Sarcopenia Muscle. 2023; 14(3): 1150-1167.

[266] Argilés JM, Fontes-Oliveira CC, Toledo M, López-Soriano FJ, Busquets S. Cachexia: a problem of energetic inefficiency. J Cachexia Sarcopenia Muscle. 2014; 5(4): 279-286.

[267] Jouinot A, Ulmann G, Vazeille C, et al. Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. Clin Nutr. 2020; 39(6): 1893-1899.

[268] Vazeille C, Jouinot A, Durand JP, et al. Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy. Am J Clin Nutr. 2017; 105(5): 1139-1147.

[269] Hsu MY, Porporato PE, Wyart E. Assessing metabolic dysregulation in muscle during cachexia. Methods Mol Biol. 2019; 1928: 337-352.

[270] Constantinou C, Fontes de Oliveira CC, Mintzopoulos D, et al. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int J Mol Med. 2011; 27(1): 15-24.

[271] Fontes-Oliveira CC, Busquets S, Toledo M, et al. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? Biochim Biophys Acta. 2013; 1830(3): 2770-2778.

[272] Marzetti E, Lorenzi M, Landi F, et al. Altered mitochondrial quality control signaling in muscle of old gastric cancer patients with cachexia. Exp Gerontol. 2017; 87(Pt A): 92-99.

[273] Fouladiun M, Körner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care–correlations with food intake, metabolism, exercise capacity, and hormones. Cancer. 2005; 103(10): 2189-2198.

[274] Dahlman I, Mejhert N, Linder K, et al. Adipose tissue pathways involved in weight loss of cancer cachexia. Br J Cancer. 2010; 102(10): 1541-1548.

[275] Mracek T, Stephens NA, Gao D, et al. Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br J Cancer. 2011; 104(3): 441-447.

[276] Alves MJ, Figuerêdo RG, Azevedo FF, et al. Adipose tissue fibrosis in human cancer cachexia: the role of TGFβ pathway. BMC Cancer. 2017; 17(1): 190.

[277] Batista ML, Jr., Henriques FS, Neves RX, et al. Cachexia-associated adipose tissue morphological rearrangement in gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle. 2016; 7(1): 37-47.

[278] Rydén M, Arner P. Tumour necrosis factor-alpha in human adipose tissue – from signalling mechanisms to clinical implications. J Intern Med. 2007; 262(4): 431-438.

[279] Zuijdgeest-van Leeuwen SD, van den Berg JW, Wattimena JL, et al. Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects. Metabolism. 2000; 49(7): 931-936.

[280] Agustsson T, Rydén M, Hoffstedt J, et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007; 67(11): 5531-5537.

[281] Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 2011; 333(6039): 233-238.

[282] Rohm M, Schäfer M, Laurent V, et al. An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice. Nat Med. 2016; 22(10): 1120-1130.

[283] Stephens NA, Skipworth RJ, Macdonald AJ, Greig CA, Ross JA, Fearon KC. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle. 2011; 2(2): 111-117.

[284] Vegiopoulos A, Rohm M, Herzig S. Adipose tissue: between the extremes. EMBO J. 2017; 36(14): 1999-2017.

[285] Schmidt SF, Rohm M, Herzig S, Berriel Diaz M. Cancer cachexia: more than skeletal muscle wasting. Trends Cancer. 2018; 4(12): 849-860.

[286] Tsoli M, Moore M, Burg D, et al. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res. 2012; 72(17): 4372-4382.

[287] Arruda AP, Milanski M, Romanatto T, et al. Hypothalamic actions of tumor necrosis factor alpha provide the thermogenic core for the wastage syndrome in cachexia. Endocrinology. 2010; 151(2): 683-694.

[288] Li G, Klein RL, Matheny M, King MA, Meyer EM, Scarpace PJ. Induction of uncoupling protein 1 by central interleukin-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue and underlies one mechanism of body weight reduction in rats. Neuroscience. 2002; 115(3): 879-889.

[289] Kir S, White JP, Kleiner S, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 2014; 513(7516): 100-104.

[290] Roca-Rodríguez MM, El Bekay R, Garrido-Sanchez L, et al. Parathyroid hormone-related protein, human adipose-derived stem cells adipogenic capacity and healthy obesity. J Clin Endocrinol Metab. 2015; 100(6): E826-E835.

[291] Vilardaga JP, Romero G, Friedman PA, Gardella TJ. Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci. 2011; 68(1): 1-13.

[292] Tsoli M, Swarbrick MM, Robertson GR. Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia. Semin Cell Dev Biol. 2016; 54: 68-81.

[293] Borner T, Arnold M, Ruud J, et al. Anorexia-cachexia syndrome in hepatoma tumour-bearing rats requires the area postrema but not vagal afferents and is paralleled by increased MIC-1/GDF15. J Cachexia Sarcopenia Muscle. 2017; 8(3): 417-427.

[294] Hogan KA, Cho DS, Arneson PC, et al. Tumor-derived cytokines impair myogenesis and alter the skeletal muscle immune microenvironment. Cytokine. 2018; 107: 9-17.

[295] Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012; 150(1): 165-178.

[296] Eck M, Schmausser B, Scheller K, Brändlein S, Müller-Hermelink HK. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol. 2003; 134(3): 508-515.

[297] Seto DN, Kandarian SC, Jackman RW. A key role for leukemia inhibitory factor in C26 cancer cachexia. J Biol Chem. 2015; 290(32): 19976-19986.

[298] Kandarian SC, Nosacka RL, Delitto AE, et al. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice. J Cachexia Sarcopenia Muscle. 2018; 9(6): 1109-1120.

[299] Argilés JM, López-Soriano FJ, Busquets S. Mediators of cachexia in cancer patients. Nutrition. 2019; 66: 11-15.

[300] Capece D, Verzella D, Tessitore A, Alesse E, Capalbo C, Zazzeroni F. Cancer secretome and inflammation: the bright and the dark sides of NF-κB. Semin Cell Dev Biol. 2018; 78: 51-61.

[301] Johnston AJ, Murphy KT, Jenkinson L, et al. Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell. 2015; 162(6): 1365-1378.

[302] Armstrong VS, Fitzgerald LW, Bathe OF. Cancer-associated muscle wasting-candidate mechanisms and molecular pathways. Int J Mol Sci. 2020; 21(23): 9268.

[303] Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010; 142(4): 531-543.

[304] Pettersen K, Andersen S, van der Veen A, et al. Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia. J Cachexia Sarcopenia Muscle. 2020; 11(1): 195-207.

[305] Loumaye A, de Barsy M, Nachit M, et al. Role of Activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab. 2015; 100(5): 2030-2038.

[306] Hamilton TD, Leugner D, Kopciuk K, Dixon E, Sutherland FR, Bathe OF. Identification of prognostic inflammatory factors in colorectal liver metastases. BMC Cancer. 2014; 14: 542.

[307] Scheede-Bergdahl C, Watt HL, Trutschnigg B, et al. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clin Nutr. 2012; 31(1): 85-88.

[308] Pin F, Barreto R, Kitase Y, et al. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle. 2018; 9(4): 685-700.

[309] Chen JL, Walton KL, Winbanks CE, et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 2014; 28(4): 1711-1723.

[310] Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol. 2005; 37(10): 1974-1984.

[311] McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997; 387(6628): 83-90.

[312] Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun. 2010; 391(3): 1548-1554.

[313] Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA. 2001; 98(16): 9306-9311.

[314] Gallot YS, Durieux AC, Castells J, et al. Myostatin gene inactivation prevents skeletal muscle wasting in cancer. Cancer Res. 2014; 74(24): 7344-7356.

[315] Goodman CA, McNally RM, Hoffmann FM, Hornberger TA. Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo. Mol Endocrinol. 2013; 27(11): 1946-1957.

[316] Sartori R, Hagg A, Zampieri S, et al. Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Sci Transl Med. 2021; 13(605): eaay9592.

[317] Paajanen J, Ilonen I, Lauri H, et al. Elevated circulating activin A levels in patients with malignant pleural mesothelioma are related to cancer cachexia and reduced response to platinum-based chemotherapy. Clin Lung Cancer. 2020; 21(3): e142-e150.

[318] Marino FE, Risbridger G, Gold E. Activin-βC modulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways. J Cachexia Sarcopenia Muscle. 2015; 6(4): 365-380.

[319] Parajuli P, Kumar S, Loumaye A, et al. Twist1 activation in muscle progenitor cells causes muscle loss akin to cancer cachexia. Dev Cell. 2018; 45(6): 712-725. e6.

[320] Nissinen TA, Hentilä J, Penna F, et al. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. J Cachexia Sarcopenia Muscle. 2018; 9(3): 514-529.

[321] Chen JL, Walton KL, Qian H, et al. Differential effects of IL6 and activin A in the development of cancer-associated cachexia. Cancer Res. 2016; 76(18): 5372-5382.

[322] Judge SM, Nosacka RL, Delitto D, et al. Skeletal muscle fibrosis in pancreatic cancer patients with respect to survival. JNCI Cancer Spectr. 2018; 2(3): pky043.

[323] Johns N, Stretch C, Tan BH, et al. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle. 2017; 8(1): 122-130.

[324] Oh J, Sinha I, Tan KY, et al. Age-associated NF-κB signaling in myofibers alters the satellite cell niche and re-strains muscle stem cell function. Aging (Albany NY). 2016; 8(11): 2871-2896.

[325] Ziegelbauer K, Gantner F, Lukacs NW, et al. A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol. 2005; 145(2): 178-192.

[326] Zhang N, Valentine JM, Zhou Y, et al. Sustained NFκB inhibition improves insulin sensitivity but is detrimental to muscle health. Aging Cell. 2017; 16(4): 847-858.

[327] Di Marco S, Mazroui R, Dallaire P, et al. NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol Cell Biol. 2005; 25(15): 6533-6545.

[328] Murton AJ, Maddocks M, Stephens FB, Marimuthu K, England R, Wilcock A. Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. Clin Lung Cancer. 2017; 18(1): e1-e11.

[329] Sala D, Cunningham TJ, Stec MJ, et al. The Stat3-Fam3a axis promotes muscle stem cell myogenic lineage progression by inducing mitochondrial respiration. Nat Commun. 2019; 10(1): 1796.

[330] Hardee JP, Counts BR, Gao S, et al. Inflammatory signalling regulates eccentric contraction-induced protein synthesis in cachectic skeletal muscle. J Cachexia Sarcopenia Muscle. 2018; 9(2): 369-383.

[331] Baltgalvis KA, Berger FG, Pena MM, Davis JM, Muga SJ, Carson JA. Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol. 2008; 294(2): R393-R401.

[332] Bonetto A, Aydogdu T, Kunzevitzky N, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 2011; 6(7): e22538.

[333] Bonetto A, Aydogdu T, Jin X, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012; 303(3): E410-E421.

[334] Zanders L, Kny M, Hahn A, et al. Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting. J Cachexia Sarcopenia Muscle. 2022; 13(1): 713-727.

[335] Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med. 2016; 14: 3.

[336] Yoshida T, Delafontaine P. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020; 9(9): 1970.

[337] Cappola AR, Bandeen-Roche K, Wand GS, Volpato S, Fried LP. Association of IGF-I levels with muscle strength and mobility in older women. J Clin Endocrinol Metab. 2001; 86(9): 4139-4146.

[338] Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999; 107(2): 123-136.

[339] Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001; 86(2): 724-731.

[340] Sattler FR, Castaneda-Sceppa C, Binder EF, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab. 2009; 94(6): 1991-2001.

[341] Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149(2): 274-293.

[342] Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol. 2009; 19(22): R1046-R1052.

[343] Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020; 21(4): 183-203.

[344] Castets P, Lin S, Rion N, et al. Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. Cell Metab. 2013; 17(5): 731-744.

[345] Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017; 168(6): 960-976.

[346] Kim JE, Chen J. regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004; 53(11): 2748-2756.

[347] Polak P, Cybulski N, Feige JN, Auwerx J, Rüegg MA, Hall MN. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab. 2008; 8(5): 399-410.

[348] Agarwal S, Cholok D, Loder S, et al. mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration. JCI Insight. 2016; 1(20): e89805.

[349] Weigl LG. Lost in translation: regulation of skeletal muscle protein synthesis. Curr Opin Pharmacol. 2012; 12(3): 377-382.

[350] Schmitt TL, Martignoni ME, Bachmann J, et al. Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia. J Mol Med (Berl). 2007; 85(6): 647-654.

[351] White JP, Baynes JW, Welle SL, et al. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLoS One. 2011; 6(9): e24650.

[352] Williams JP, Phillips BE, Smith K, et al. Effect of tumor burden and subsequent surgical resection on skeletal muscle mass and protein turnover in colorectal cancer patients. Am J Clin Nutr. 2012; 96(5): 1064-1070.

[353] Hood DA, Memme JM, Oliveira AN, Triolo M. Maintenance of skeletal muscle mitochondria in health, exercise, and aging. Annu Rev Physiol. 2019; 81: 19-41.

[354] Picca A, Calvani R, Leeuwenburgh C, et al. Targeting mitochondrial quality control for treating sarcopenia: lessons from physical exercise. Expert Opin Ther Targets. 2019; 23(2): 153-160.

[355] Leduc-Gaudet JP, Hussain SNA, Barreiro E, Gouspillou G. Mitochondrial dynamics and mitophagy in skeletal muscle health and aging. Int J Mol Sci. 2021; 22(15): 8179.

[356] Marzetti E, Calvani R, Cesari M, et al. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. Int J Biochem Cell Biol. 2013; 45(10): 2288-2301.

[357] Chen C, Zhou M, Ge Y, Wang X. SIRT1 and aging related signaling pathways. Mech Ageing Dev. 2020; 187: 111215.

[358] Nakamura MT, Yudell BE, Loor JJ. Regulation of energy metabolism by long-chain fatty acids. Prog Lipid Res. 2014; 53: 124-144.

[359] Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol. 2017; 13(10): 629-646.

[360] Kang C, Chung E, Diffee G, Ji LL. Exercise training attenuates aging-associated mitochondrial dysfunction in rat skeletal muscle: role of PGC-1α. Exp Gerontol. 2013; 48(11): 1343-1350.

[361] Konopka AR, Suer MK, Wolff CA, Harber MP. Markers of human skeletal muscle mitochondrial biogenesis and quality control: effects of age and aerobic exercise training. J Gerontol A Biol Sci Med Sci. 2014; 69(4): 371-378.

[362] Argilés JM, López-Soriano FJ, Busquets S. Muscle wasting in cancer: the role of mitochondria. Curr Opin Clin Nutr Metab Care. 2015; 18(3): 221-225.

[363] Barreto R, Mandili G, Witzmann FA, Novelli F, Zimmers TA, Bonetto A. Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front Physiol. 2016; 7: 472.

[364] van der Ende M, Grefte S, Plas R, et al. Mitochondrial dynamics in cancer-induced cachexia. Biochim Biophys Acta Rev Cancer. 2018; 1870(2): 137-150.

[365] Penna F, Ballarò R, Martinez-Cristobal P, et al. Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J Mol Biol. 2019; 431(15): 2674-2686.

[366] Molinari F, Pin F, Gorini S, et al. The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J Cachexia Sarcopenia Muscle. 2017; 8(6): 954-973.

[367] Argilés JM, López-Soriano FJ, Stemmler B, Busquets S. Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management. Nat Rev Clin Oncol. 2023; 20(4): 250-264.

[368] Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012; 8(8): 457-465.

[369] Pedersen BK. Physical activity and muscle-brain crosstalk. Nat Rev Endocrinol. 2019; 15(7): 383-392.

[370] Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005; 115(5): 911-919; quiz 920.

[371] Picca A, Calvani R, Cesari M, et al. Biomarkers of physical frailty and sarcopenia: coming up to the place? Int J Mol Sci. 2020; 21(16): 5635.

[372] Rong S, Wang L, Peng Z, et al. The mechanisms and treatments for sarcopenia: could exosomes be a perspective research strategy in the future? J Cachexia Sarcopenia Muscle. 2020; 11(2): 348-365.

[373] Huang Z, Xu A. Adipose extracellular vesicles in intercellular and inter-organ crosstalk in metabolic health and diseases. Front Immunol. 2021; 12: 608680.

[374] Figliolini F, Ranghino A, Grange C, et al. Extracellular vesicles from adipose stem cells prevent muscle damage and inflammation in a mouse model of hind limb ischemia: role of neuregulin-1. Arterioscler Thromb Vasc Biol. 2020; 40(1): 239-254.

[375] Pereira S, Cline DL, Glavas MM, Covey SD, Kieffer TJ. Tissue-specific effects of leptin on glucose and lipid metabolism. Endocr Rev. 2021; 42(1): 1-28.

[376] Huan JN, Li J, Han Y, Chen K, Wu N, Zhao AZ. Adipocyte-selective reduction of the leptin receptors induced by antisense RNA leads to increased adiposity, dyslipidemia, and insulin resistance. J Biol Chem. 2003; 278(46): 45638-45650.

[377] Masuzaki H, Ogawa Y, Isse N, et al. Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue. Diabetes. 1995; 44(7): 855-858.

[378] Pérez C, Fernández-Galaz C, Fernández-Agulló T, et al. Leptin impairs insulin signaling in rat adipocytes. Diabetes. 2004; 53(2): 347-353.

[379] Müller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem. 1997; 272(16): 10585-10593.

[380] Fischer AW, Hoefig CS, Abreu-Vieira G, et al. Leptin raises defended body temperature without activating thermogenesis. Cell Rep. 2016; 14(7): 1621-1631.

[381] Wang P, Loh KH, Wu M, et al. A leptin-BDNF pathway regulating sympathetic innervation of adipose tissue. Nature. 2020; 583(7818): 839-844.

[382] Sáinz N, Rodríguez A, Catalán V, et al. Leptin administration favors muscle mass accretion by decreasing FoxO3a and increasing PGC-1alpha in ob/ob mice. PLoS One. 2009; 4(9): e6808.

[383] Rodríguez A, Becerril S, Méndez-Giménez L, et al. Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice. Int J Obes (Lond). 2015; 39(3): 397-407.

[384] Pijet M, Pijet B, Litwiniuk A, Pajak B, Gajkowska B, Orzechowski A. Leptin impairs myogenesis in C2C12 cells through JAK/STAT and MEK signaling pathways. Cytokine. 2013; 61(2): 445-454.

[385] Han L, Wang G, Zhou S, et al. Muscle satellite cells are impaired in type 2 diabetic mice by elevated extracellular adenosine. Cell Rep. 2022; 39(9): 110884.

[386] Akasaka Y, Tsunoda M, Ogata T, Ide T, Murakami K. Direct evidence for leptin-induced lipid oxidation independent of long-form leptin receptor. Biochim Biophys Acta. 2010; 1801(10): 1115-1122.

[387] Koo YD, Lee JS, Lee SA, et al. SUMO-specific protease 2 mediates leptin-induced fatty acid oxidation in skeletal muscle. Metabolism. 2019; 95: 27-35.

[388] Dulloo AG, Stock MJ, Solinas G, Boss O, Montani JP, Seydoux J. Leptin directly stimulates thermogenesis in skeletal muscle. FEBS Lett. 2002; 515(1-3): 109-113.

[389] Harris RB. Acute and chronic effects of leptin on glucose utilization in lean mice. Biochem Biophys Res Commun. 1998; 245(2): 502-509.

[390] Ceddia RB, William WN, Jr., Curi R. Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: evidence for an effect of leptin on glucose uptake and decarboxylation. Int J Obes Relat Metab Disord. 1999; 23(1): 75-82.

[391] Berti L, Kellerer M, Capp E, Häring HU. Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: evidence for a P13-kinase mediated effect. Diabetologia. 1997; 40(5): 606-609.

[392] Kohara K, Ochi M, Tabara Y, Nagai T, Igase M, Miki T. Leptin in sarcopenic visceral obesity: possible link between adipocytes and myocytes. PLoS One. 2011; 6(9): e24633.

[393] Li CW, Yu K, Shyh-Chang N, et al. Circulating factors associated with sarcopenia during ageing and after intensive lifestyle intervention. J Cachexia Sarcopenia Muscle. 2019; 10(3): 586-600.

[394] Lana A, Valdés-Bécares A, Buño A, Rodríguez-Artalejo F, Lopez-Garcia E. Serum leptin concentration is associated with incident frailty in older adults. Aging Dis. 2017; 8(2): 240-249.

[395] Guadalupe-Grau A, Larsen S, Guerra B, Calbet JA, Dela F, Helge JW. Influence of age on leptin induced skeletal muscle signalling. Acta Physiol (Oxf). 2014; 211(1): 214-228.

[396] Manoy P, Anomasiri W, Yuktanandana P, et al. Elevated serum leptin levels are associated with low vitamin D, sarcopenic obesity, poor muscle strength, and physical performance in knee osteoarthritis(). Biomarkers. 2017; 22(8): 723-730.

[397] Minokoshi Y, Toda C, Okamoto S. Regulatory role of leptin in glucose and lipid metabolism in skeletal muscle. Indian J Endocrinol Metab. 2012; 16(Suppl 3): S562-S568.

[398] Sáinz N, Barrenetxe J, Moreno-Aliaga MJ, Martínez JA. Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism. 2015; 64(1): 35-46.

[399] Wu L, Chen G, Liu W, et al. Intramuscular injection of exogenous leptin induces adiposity, glucose intolerance and fatty liver by repressing the JAK2-STAT3/PI3K pathway in a rat model. Gen Compar Endocrinol. 2017; 252: 88-96.

[400] Kob R, Bollheimer LC, Bertsch T, et al. Sarcopenic obesity: molecular clues to a better understanding of its pathogenesis? Biogerontology. 2015; 16(1): 15-29.

[401] Stinkens R, Goossens GH, Jocken JW, Blaak EE. Targeting fatty acid metabolism to improve glucose metabolism. Obes Rev. 2015; 16(9): 715-757.

[402] Hamrick MW, McGee-Lawrence ME, Frechette DM. Fatty infiltration of skeletal muscle: mechanisms and comparisons with bone marrow adiposity. Front Endocrinol (Lausanne). 2016; 7: 69.

[403] Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf). 2006; 186(1): 5-16.

[404] Scarpace PJ, Matheny M, Tümer N, Cheng KY, Zhang Y. Leptin resistance exacerbates diet-induced obesity and is associated with diminished maximal leptin signalling capacity in rats. Diabetologia. 2005; 48(6): 1075-1083.

[405] Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006; 17(1): 4-12.

[406] Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016; 23(5): 770-784.

[407] Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014; 15(4): 6184-6223.

[408] Suriano F, Vieira-Silva S, Falony G, et al. Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin. Microbiome. 2021; 9(1): 147.

[409] Naveilhan P, Svensson L, Nyström S, Ekstrand AJ, Ernfors P. Attenuation of hypercholesterolemia and hyperglycemia in ob/ob mice by NPY Y2 receptor ablation. Peptides. 2002; 23(6): 1087-1091.

[410] Iacobellis G, Di Gioia C, Petramala L, et al. Brown fat expresses adiponectin in humans. Int J Endocrinol. 2013; 2013: 126751.

[411] Andrade ML, Gilio GR, Perandini LA, et al. PPARγ-induced upregulation of subcutaneous fat adiponectin secretion, glyceroneogenesis and BCAA oxidation requires mTORC1 activity. Biochim Biophys Acta Mol Cell Biol Lipids. 2021; 1866(8): 158967.

[412] Inoue A, Cheng XW, Huang Z, et al. Exercise restores muscle stem cell mobilization, regenerative capacity and muscle metabolic alterations via adiponectin/AdipoR1 activation in SAMP10 mice. J Cachexia Sarcopenia Muscle. 2017; 8(3): 370-385.

[413] Singh AK, Shree S, Chattopadhyay S, et al. Small molecule adiponectin receptor agonist GTDF protects against skeletal muscle atrophy. Mol Cell Endocrinol. 2017; 439: 273-285.

[414] Song A, Dai W, Jang MJ, et al. Low-and high-thermogenic brown adipocyte subpopulations coexist in murine adipose tissue. J Clin Invest. 2020; 130(1): 247-257.

[415] Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes. 2006; 55(9): 2562-2570.

[416] Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005; 26(3): 439-451.

[417] Sente T, Van Berendoncks AM, Hoymans VY, Vrints CJ. Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. J Cachexia Sarcopenia Muscle. 2016; 7(3): 261-274.

[418] Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia. 2005; 48(1): 132-139.

[419] Gamberi T, Modesti A, Magherini F, D’Souza DM, Hawke T, Fiaschi T. Activation of autophagy by globular adiponectin is required for muscle differentiation. Biochim Biophys Acta. 2016; 1863(4): 694-702.

[420] Lee MH, Klein RL, El-Shewy HM, Luttrell DK, Luttrell LM. The adiponectin receptors AdipoR1 and AdipoR2 activate ERK1/2 through a Src/Ras-dependent pathway and stimulate cell growth. Biochemistry. 2008; 47(44): 11682-11692.

[421] Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010; 464(7293): 1313-1319.

[422] Can B, Kara O, Kizilarslanoglu MC, et al. Serum markers of inflammation and oxidative stress in sarcopenia. Aging Clin Exp Res. 2017; 29(4): 745-752.

[423] Baker JF, Newman AB, Kanaya A, et al. The adiponectin paradox in the elderly: associations with body composition, physical functioning, and mortality. J Gerontol A Biol Sci Med Sci. 2019; 74(2): 247-253.

[424] Vella CA, Cushman M, Van Hollebeke RB, Allison MA. Associations of abdominal muscle area and radiodensity with adiponectin and leptin: the multiethnic study of atherosclerosis. Obesity (Silver Spring). 2018; 26(7): 1234-1241.

[425] Rossi FE, Lira FS, Silva BSA, Freire A, Ramos EMC, Gobbo LA. Influence of skeletal muscle mass and fat mass on the metabolic and inflammatory profile in sarcopenic and non-sarcopenic overfat elderly. Aging Clin Exp Res. 2019; 31(5): 629-635.

[426] Paris MT, Bell KE, Mourtzakis M. Myokines and adipokines in sarcopenia: understanding cross-talk between skeletal muscle and adipose tissue and the role of exercise. Curr Opin Pharmacol. 2020; 52: 61-66.

[427] Huang C, Tomata Y, Kakizaki M, et al. High circulating adiponectin levels predict decreased muscle strength among older adults aged 70 years and over: A prospective cohort study. Nutr Metab Cardiovasc Dis. 2015; 25(6): 594-601.

[428] Hui X, Gu P, Zhang J, et al. Adiponectin enhances cold-induced browning of subcutaneous adipose tissue via promoting M2 macrophage proliferation. Cell Metab. 2015; 22(2): 279-290.

[429] Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7(8): 941-946.

[430] Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007; 13(3): 332-339.

[431] Voss SC, Nikolovski Z, Bourdon PC, Alsayrafi M, Schumacher YO. The effect of cumulative endurance exercise on leptin and adiponectin and their role as markers to monitor training load. Biol Sport. 2016; 33(1): 23-28.

[432] Gondim OS, de Camargo VT, Gutierrez FA, et al. Benefits of regular exercise on inflammatory and cardiovascular risk markers in normal weight, overweight and obese adults. PLoS One. 2015; 10(10): e0140596.

[433] Bertevello PS, Seelaender MC. Heterogeneous response of adipose tissue to cancer cachexia. Braz J Med Biol Res. 2001; 34(9): 1161-1167.

[434] Machado AP, Costa Rosa LF, Seelaender MC. Adipose tissue in Walker 256 tumour-induced cachexia: possible association between decreased leptin concentration and mononuclear cell infiltration. Cell Tissue Res. 2004; 318(3): 503-514.

[435] Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818): 307-312.

[436] Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem. 2001; 276(14): 11252-11256.

[437] Palanivel R, Sweeney G. Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin. FEBS Lett. 2005; 579(22): 5049-5054.

[438] Palanivel R, Maida A, Liu Y, Sweeney G. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia. 2006; 49(1): 183-190.

[439] O’Leary MF, Wallace GR, Davis ET, et al. Obese subcutaneous adipose tissue impairs human myogenesis, particularly in old skeletal muscle, via resistin-mediated activation of NFκB. Sci Rep. 2018; 8(1): 15360.

[440] Sheng CH, Du ZW, Song Y, et al. Human resistin inhibits myogenic differentiation and induces insulin resistance in myocytes. Biomed Res Int. 2013; 2013: 804632.

[441] Won JC, Park CY, Lee WY, Lee ES, Oh SW, Park SW. Association of plasma levels of resistin with subcutaneous fat mass and markers of inflammation but not with metabolic determinants or insulin resistance. J Korean Med Sci. 2009; 24(4): 695-700.

[442] Bucci L, Yani SL, Fabbri C, et al. Circulating levels of adipokines and IGF-1 are associated with skeletal muscle strength of young and old healthy subjects. Biogerontology. 2013; 14(3): 261-272.

[443] Gu X, Wang L, Liu S, Shan T. Adipose tissue adipokines and lipokines: functions and regulatory mechanism in skeletal muscle development and homeostasis. Metabolism. 2023; 139: 155379.

[444] Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005; 174(9): 5789-5795.

[445] Lutz CT, Quinn LS. Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging (Albany NY). 2012; 4(8): 535-546.

[446] Gong WJ, Zheng W, Xiao L, et al. Circulating resistin levels and obesity-related cancer risk: a meta-analysis. Oncotarget. 2016; 7(36): 57694-57704.

[447] Kumor A, Daniel P, Pietruczuk M, Małecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis. 2009; 24(3): 275-281.

[448] Demiray G, Değirmencioğlu S, Uğurlu E, Yaren A. Effects of serum leptin and resistin levels on cancer cachexia in patients with advanced-stage non-small cell lung cancer. Clin Med Insights Oncol. 2017; 11: 1179554917690144.

[449] Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol. 2009; 44(7): 685-690.

[450] Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014; 6(10): a016295.

[451] Uezumi A, Fukada S, Yamamoto N, Takeda S, Tsuchida K. Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat Cell Biol. 2010; 12(2): 143-152.

[452] Muñoz-Cánoves P, Scheele C, Pedersen BK, Serrano AL. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J. 2013; 280(17): 4131-4148.

[453] Serrano AL, Baeza-Raja B, Perdiguero E, Jardí M, Muñoz-Cánoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008; 7(1): 33-44.

[454] Tierney MT, Aydogdu T, Sala D, et al. STAT3 signaling controls satellite cell expansion and skeletal muscle repair. Nat Med. 2014; 20(10): 1182-1186.

[455] Keller C, Steensberg A, Pilegaard H, et al. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J. 2001; 15(14): 2748-2750.

[456] Steensberg A, Febbraio MA, Osada T, et al. Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol. 2001; 537(Pt 2): 633-639.

[457] Febbraio MA, Steensberg A, Keller C, et al. Glucose ingestion attenuates interleukin-6 release from contracting skeletal muscle in humans. J Physiol. 2003; 549(Pt 2): 607-612.

[458] Carey AL, Steinberg GR, Macaulay SL, et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006; 55(10): 2688-2697.

[459] Glund S, Deshmukh A, Long YC, et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes. 2007; 56(6): 1630-1637.

[460] Bruce CR, Dyck DJ. Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab. 2004; 287(4): E616-E621.

[461] Knudsen JG, Gudiksen A, Bertholdt L, et al. Skeletal muscle IL-6 regulates muscle substrate utilization and adipose tissue metabolism during recovery from an acute bout of exercise. PLoS One. 2017; 12(12): e0189301.

[462] Kelly M, Keller C, Avilucea PR, et al. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun. 2004; 320(2): 449-454.

[463] Shan T, Liang X, Bi P, Kuang S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1α-Fndc5 pathway in muscle. FASEB J. 2013; 27(5): 1981-1989.

[464] Knudsen JG, Murholm M, Carey AL, et al. Role of IL-6 in exercise training-and cold-induced UCP1 expression in subcutaneous white adipose tissue. PLoS One. 2014; 9(1): e84910.

[465] Xuan MF, Luo ZB, Han SZ, et al. Skeletal muscle-secreted myokine interleukin-6 induces white adipose tissue conversion into beige adipose tissue in myostatin gene knockout pigs. Domest Anim Endocrinol. 2022; 78: 106679.

[466] Whitham M, Pal M, Petzold T, et al. Adipocyte-specific deletion of IL-6 does not attenuate obesity-induced weight gain or glucose intolerance in mice. Am J Physiol Endocrinol Metab. 2019; 317(4): E597-E604.

[467] Jonas MI, Kurylowicz A, Bartoszewicz Z, et al. Interleukins 6 and 15 levels are higher in subcutaneous adipose tissue, but obesity is associated with their increased content in visceral fat depots. Int J Mol Sci. 2015; 16(10): 25817-25830.

[468] Ohlson LO, Larsson B, Svärdsudd K, et al. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes. 1985; 34(10): 1055-1058.

[469] Sepulveda-Lavados A, Bastard JP, Attal M, et al. Association between intra-abdominal fat and hypertension in android obese diabetics. Ann Med Interne (Paris). 1996; 147(6): 393-316.

[470] Nelke C, Dziewas R, Minnerup J, Meuth SG, Ruck T. Skeletal muscle as potential central link between sarcopenia and immune senescence. EBioMedicine. 2019; 49: 381-388.

[471] Picca A, Coelho-Junior HJ, Calvani R, Marzetti E, Vetrano DL. Biomarkers shared by frailty and sarcopenia in older adults: a systematic review and meta-analysis. Ageing Res Rev. 2022; 73: 101530.

[472] Rong YD, Bian AL, Hu HY, Ma Y, Zhou XZ. Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6, anti-inflammatory cytokine IL-10. BMC Geriatr. 2018; 18(1): 308.

[473] Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006; 119(6): 526. e9-e17.

[474] White JP, Puppa MJ, Sato S, et al. IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse. Skelet Muscle. 2012; 2: 14.

[475] Ebisui C, Tsujinaka T, Morimoto T, et al. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes. Clin Sci (Lond). 1995; 89(4): 431-439.

[476] Madaro L, Passafaro M, Sala D, et al. Denervation-activated STAT3-IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis. Nat Cell Biol. 2018; 20(8): 917-927.

[477] Pelosi M, De Rossi M, Barberi L, Musarò A. IL-6 impairs myogenic differentiation by downmodulation of p90RSK/eEF2 and mTOR/p70S6K axes, without affecting AKT activity. Biomed Res Int. 2014; 2014: 206026.

[478] Fix DK, VanderVeen BN, Counts BR, Carson JA. Regulation of skeletal muscle DRP-1 and FIS-1 protein expression by IL-6 signaling. Oxid Med Cell Longev. 2019; 2019: 8908457.

[479] Carson JA, Hardee JP, VanderVeen BN. The emerging role of skeletal muscle oxidative metabolism as a biological target and cellular regulator of cancer-induced muscle wasting. Semin Cell Dev Biol. 2016; 54: 53-67.

[480] Drake JC, Wilson RJ, Yan Z. Molecular mechanisms for mitochondrial adaptation to exercise training in skeletal muscle. FASEB J. 2016; 30(1): 13-22.

[481] Romanello V, Guadagnin E, Gomes L, et al. Mitochondrial fission and remodelling contributes to muscle atrophy. EMBO J. 2010; 29(10): 1774-1785.

[482] Mishra P, Chan DC. Metabolic regulation of mitochondrial dynamics. J Cell Biol. 2016; 212(4): 379-387.

[483] Jheng HF, Tsai PJ, Guo SM, et al. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. Mol Cell Biol. 2012; 32(2): 309-319.

[484] Wai T, Langer T. Mitochondrial dynamics and metabolic regulation. Trends Endocrinol Metab. 2016; 27(2): 105-117.

[485] Ding H, Jiang N, Liu H, et al. Response of mitochondrial fusion and fission protein gene expression to exercise in rat skeletal muscle. Biochim Biophys Acta. 2010; 1800(3): 250-256.

[486] Williams A, Wang JJ, Wang L, Sun X, Fischer JE, Hasselgren PO. Sepsis in mice stimulates muscle proteolysis in the absence of IL-6. Am J Physiol. 1998; 275(6): R1983-R1991.

[487] Tan BH, Ross JA, Kaasa S, Skorpen F, Fearon KC. Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review. J Genet. 2011; 90(1): 165-177.

[488] Najdaghi S, Razi S, Rezaei N. An overview of the role of interleukin-8 in colorectal cancer. Cytokine. 2020; 135: 155205.

[489] Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK. Chemokines are elevated in plasma after strenuous exercise in humans. Eur J Appl Physiol. 2001; 84(3): 244-245.

[490] Nieman DC, Henson DA, Smith LL, et al. Cytokine changes after a marathon race. J Appl Physiol (1985). 2001; 91(1): 109-114.

[491] Nieman DC, Davis JM, Henson DA, et al. Carbohydrate ingestion influences skeletal muscle cytokine mRNA and plasma cytokine levels after a 3-h run. J Appl Physiol (1985). 2003; 94(5): 1917-1925.

[492] Hangelbroek RWJ, Knuiman P, Tieland M, de Groot L. Attenuated strength gains during prolonged resistance exercise training in older adults with high inflammatory status. Exp Gerontol. 2018; 106: 154-158.

[493] Westbury LD, Fuggle NR, Syddall HE, et al. Relationships between markers of inflammation and muscle mass, strength and function: findings from the hertfordshire cohort study. Calcif Tissue Int. 2018; 102(3): 287-295.

[494] Fan Z, Yang JY, Guo Y, Liu YX, Zhong XY. Altered levels of circulating mitochondrial DNA in elderly people with sarcopenia: association with mitochondrial impairment. Exp Gerontol. 2022; 163: 111802.

[495] Amir Levy Y, Ciaraldi TP, Mudaliar SR, Phillips SA, Henry RR. Excessive secretion of IL-8 by skeletal muscle in type 2 diabetes impairs tube growth: potential role of PI3K and the Tie2 receptor. Am J Physiol Endocrinol Metab. 2015; 309(1): E22-E34.

[496] Guo A, Li K, Xiao Q. Sarcopenic obesity: Myokines as potential diagnostic biomarkers and therapeutic targets? Exp Gerontol. 2020; 139: 111022.

[497] Bruun JM, Lihn AS, Madan AK, et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab. 2004; 286(1): E8-E13.

[498] Straczkowski M, Dzienis-Straczkowska S, Stêpieñ A, Kowalska I, Szelachowska M, Kinalska I. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab. 2002; 87(10): 4602-4606.

[499] Bruun JM, Nielsen CB, Pedersen SB, Flyvbjerg A, Richelsen B. Estrogen reduces pro-inflammatory cytokines in rodent adipose tissue: studies in vivo and in vitro. Horm Metab Res. 2003; 35(3): 142-146.

[500] Alvehus M, Simonyte K, Andersson T, et al. Adipose tissue IL-8 is increased in normal weight women after menopause and reduced after gastric bypass surgery in obese women. Clin Endocrinol (Oxf). 2012; 77(5): 684-690.

[501] Lihn AS, Pedersen SB, Lund S, Richelsen B. The anti-diabetic AMPK activator AICAR reduces IL-6 and IL-8 in human adipose tissue and skeletal muscle cells. Mol Cell Endocrinol. 2008; 292(1-2): 36-41.

[502] Kobashi C, Asamizu S, Ishiki M, et al. Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathway. J Inflamm (Lond). 2009; 6: 25.

[503] Samaras K, Botelho NK, Chisholm DJ, Lord RV. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity (Silver Spring). 2010; 18(5): 884-889.

[504] Kim CS, Park HS, Kawada T, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes. 2006; 30(9): 1347-1355.

[505] Gerhardt CC, Romero IA, Cancello R, Camoin L, Strosberg AD. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol. 2001; 175(1-2): 81-92.

[506] Hou YC, Wang CJ, Chao YJ, et al. Elevated serum interleukin-8 level correlates with cancer-related cachexia and sarcopenia: an indicator for pancreatic cancer outcomes. J Clin Med. 2018; 7(12): 502.

[507] Song B, Zhang D, Wang S, Zheng H, Wang X. Association of interleukin-8 with cachexia from patients with low-third gastric cancer. Comp Funct Genomics. 2009; 2009: 212345.

[508] Bo S, Dianliang Z, Hongmei Z, Xinxiang W, Yanbing Z, Xiaobo L. Association of interleukin-8 gene polymorphism with cachexia from patients with gastric cancer. J Interferon Cytokine Res. 2010; 30(1): 9-14.

[509] Tamura Y, Watanabe K, Kantani T, Hayashi J, Ishida N, Kaneki M. Upregulation of circulating IL-15 by treadmill running in healthy individuals: is IL-15 an endocrine mediator of the beneficial effects of endurance exercise? Endocr J. 2011; 58(3): 211-215.

[510] O’Leary MF, Wallace GR, Bennett AJ, Tsintzas K, Jones SW. IL-15 promotes human myogenesis and mitigates the detrimental effects of TNFα on myotube development. Sci Rep. 2017; 7(1): 12997.

[511] Quinn LS, Anderson BG, Drivdahl RH, Alvarez B, Argilés JM. Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: implications for treatment of muscle wasting disorders. Exp Cell Res. 2002; 280(1): 55-63.

[512] Carbó N, López-Soriano J, Costelli P, et al. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer. 2000; 83(4): 526-531.

[513] Busquets S, Figueras MT, Meijsing S, et al. Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. Int J Mol Med. 2005; 16(3): 471-476.

[514] Gray SR, Kamolrat T. The effect of exercise induced cytokines on insulin stimulated glucose transport in C2C12 cells. Cytokine. 2011; 55(2): 221-228.

[515] Krolopp JE, Thornton SM, Abbott MJ. IL-15 activates the Jak3/STAT3 signaling pathway to mediate glucose uptake in skeletal muscle cells. Front Physiol. 2016; 7: 626.

[516] Crane JD, MacNeil LG, Lally JS, et al. Exercise-stimulated interleukin-15 is controlled by AMPK and regulates skin metabolism and aging. Aging Cell. 2015; 14(4): 625-634.

[517] Quinn LS, Anderson BG, Conner JD, Pistilli EE, Wolden-Hanson T. Overexpression of interleukin-15 in mice promotes resistance to diet-induced obesity, increased insulin sensitivity, and markers of oxidative skeletal muscle metabolism. Int J Interferon Cytokine Mediat Res. 2011; 3: 29-42.

[518] Barra NG, Palanivel R, Denou E, et al. Interleukin-15 modulates adipose tissue by altering mitochondrial mass and activity. PLoS One. 2014; 9(12): e114799.

[519] Quinn LS, Strait-Bodey L, Anderson BG, Argilés JM, Havel PJ. Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. Cell Biol Int. 2005; 29(6): 449-457.

[520] Kopinke D, Roberson EC, Reiter JF. Ciliary hedgehog signaling restricts injury-induced adipogenesis. Cell. 2017; 170(2): 340-351. e12.

[521] Yalcin A, Silay K, Balik AR, Avcioğlu G, Aydin AS. The relationship between plasma interleukin-15 levels and sarcopenia in outpatient older people. Aging Clin Exp Res. 2018; 30(7): 783-790.

[522] Quinn LS, Anderson BG, Strait-Bodey L, Wolden-Hanson T. Serum and muscle interleukin-15 levels decrease in aging mice: correlation with declines in soluble interleukin-15 receptor alpha expression. Exp Gerontol. 2010; 45(2): 106-112.

[523] Quinn LS. Interleukin-15: a muscle-derived cytokine regulating fat-to-lean body composition. J Anim Sci. 2008; 86(14 Suppl): E75-E83.

[524] Nielsen AR, Hojman P, Erikstrup C, et al. Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass. J Clin Endocrinol Metab. 2008; 93(11): 4486-4493.

[525] Martínez-Hernández PL, Hernanz-Macías Á, Gómez-Candela C, et al. Serum interleukin-15 levels in cancer patients with cachexia. Oncol Rep. 2012; 28(4): 1443-1452.

[526] Lourenco MV, Frozza RL, de Freitas GB, et al. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models. Nat Med. 2019; 25(1): 165-175.

[527] Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481(7382): 463-468.

[528] Roca-Rivada A, Castelao C, Senin LL, et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One. 2013; 8(4): e60563.

[529] Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012; 61(12): 1725-1738.

[530] Kim HJ, So B, Choi M, Kang D, Song W. Resistance exercise training increases the expression of irisin concomitant with improvement of muscle function in aging mice and humans. Exp Gerontol. 2015; 70: 11-17.

[531] Chang JS, Kim TH, Nguyen TT, Park KS, Kim N, Kong ID. Circulating irisin levels as a predictive biomarker for sarcopenia: a cross-sectional community-based study. Geriatr Gerontol Int. 2017; 17(11): 2266-2273.

[532] Park HS, Kim HC, Zhang D, Yeom H, Lim SK. The novel myokine irisin: clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women. Endocrine. 2019; 64(2): 341-348.

[533] Huh JY, Dincer F, Mesfum E, Mantzoros CS. Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans. Int J Obes (Lond). 2014; 38(12): 1538-1544.

[534] Chang JS, Kong ID. Irisin prevents dexamethasone-induced atrophy in C2C12 myotubes. Pflugers Arch. 2020; 472(4): 495-502.

[535] Huh JY, Mougios V, Kabasakalis A, et al. Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metab. 2014; 99(11): E2154-E2161.

[536] Xin C, Liu J, Zhang J, et al. Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway. Int J Obes (Lond). 2016; 40(3): 443-451.

[537] Vaughan RA, Gannon NP, Mermier CM, Conn CA. Irisin, a unique non-inflammatory myokine in stimulating skeletal muscle metabolism. J Physiol Biochem. 2015; 71(4): 679-689.

[538] Vaughan RA, Gannon NP, Barberena MA, et al. Characterization of the metabolic effects of irisin on skeletal muscle in vitro. Diabetes Obes Metab. 2014; 16(8): 711-718.

[539] Reza MM, Subramaniyam N, Sim CM, et al. Irisin is a pro-myogenic factor that induces skeletal muscle hypertrophy and rescues denervation-induced atrophy. Nat Commun. 2017; 8(1): 1104.

[540] Xiong XQ, Chen D, Sun HJ, et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochim Biophys Acta. 2015; 1852(9): 1867-1875.

[541] Li DJ, Huang F, Lu WJ, Jiang GJ, Deng YP, Shen FM. Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation. Acta Physiol (Oxf). 2015; 213(3): 711-7121.

[542] Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides. 2013; 39: 125-130.

[543] Park KH, Zaichenko L, Brinkoetter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013; 98(12): 4899-4907.

[544] Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013; 98(4): E769-E778.

[545] Guo M, Yao J, Li J, et al. Irisin ameliorates age-associated sarcopenia and metabolic dysfunction. J Cachexia Sarcopenia Muscle. 2023; 14(1): 391-405.

[546] Reza MM, Sim CM, Subramaniyam N, et al. Irisin treatment improves healing of dystrophic skeletal muscle. Oncotarget. 2017; 8(58): 98553-98566.

[547] McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol. 2003; 162(6): 1135-1147.

[548] Rooks D, Praestgaard J, Hariry S, et al. Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc. 2017; 65(9): 1988-1995.

[549] Rooks D, Swan T, Goswami B, et al. Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial. JAMA Netw Open. 2020; 3(10): e2020836.

[550] Milan G, Dalla Nora E, Pilon C, et al. Changes in muscle myostatin expression in obese subjects after weight loss. J Clin Endocrinol Metab. 2004; 89(6): 2724-2727.

[551] Lin J, Arnold HB, Della-Fera MA, Azain MJ, Hartzell DL, Baile CA. Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem Biophys Res Commun. 2002; 291(3): 701-706.

[552] McPherron AC, Lee SJ. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest. 2002; 109(5): 595-601.

[553] Zhang C, McFarlane C, Lokireddy S, et al. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia. 2012; 55(1): 183-193.

[554] Artaza JN, Bhasin S, Magee TR, et al. Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multipotent cells. Endocrinology. 2005; 146(8): 3547-3557.

[555] Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol. 2003; 23(20): 7230-7242.

[556] Li F, Yang H, Duan Y, Yin Y. Myostatin regulates preadipocyte differentiation and lipid metabolism of adipocyte via ERK1/2. Cell Biol Int. 2011; 35(11): 1141-1146.

[557] Bo Li Z, Zhang J, Wagner KR. Inhibition of myostatin reverses muscle fibrosis through apoptosis. J Cell Sci. 2012; 125(Pt 17): 3957-3965.

[558] Li ZB, Kollias HD, Wagner KR. Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem. 2008; 283(28): 19371-19378.

[559] Dong J, Dong Y, Chen Z, Mitch WE, Zhang L. The pathway to muscle fibrosis depends on myostatin stimulating the differentiation of fibro/adipogenic progenitor cells in chronic kidney disease. Kidney Int. 2017; 91(1): 119-128.

[560] Braga M, Pervin S, Norris K, Bhasin S, Singh R. Inhibition of in vitro and in vivo brown fat differentiation program by myostatin. Obesity. 2013; 21(6): 1180-1188.

[561] Shan T, Liang X, Bi P, Kuang S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1α-Fndc5 pathway in muscle. FASEB J. 2013; 27(5): 1981-1989.

[562] Kim WK, Choi HR, Park SG, Ko Y, Bae KH, Lee SC. Myostatin inhibits brown adipocyte differentiation via regulation of Smad3-mediated β-catenin stabilization. Int J Biochem Cell Biol. 2012; 44(2): 327-334.

[563] Fournier B, Murray B, Gutzwiller S, et al. Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism. Mol Cell Biol. 2012; 32(14): 2871-2879.

[564] Braga M, Pervin S, Norris K, Bhasin S, Singh R. Inhibition of in vitro and in vivo brown fat differentiation program by myostatin. Obesity (Silver Spring). 2013; 21(6): 1180-1188.

[565] Kong X, Yao T, Zhou P, et al. Brown adipose tissue controls skeletal muscle function via the secretion of myostatin. Cell Metab. 2018; 28(4): 631-643. e3.

[566] Hittel DS, Berggren JR, Shearer J, Boyle K, Houmard JA. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes. 2009; 58(1): 30-38.

[567] Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O, McPherron AC. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One. 2009; 4(3): e4937.

[568] Han DS, Chang KV, Li CM, et al. Skeletal muscle mass adjusted by height correlated better with muscular functions than that adjusted by body weight in defining sarcopenia. Sci Rep. 2016; 6: 19457.

[569] Léger B, Derave W, De Bock K, Hespel P, Russell AP. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res. 2008; 11(1): 163-175b.

[570] Raue U, Slivka D, Jemiolo B, Hollon C, Trappe S. Myogenic gene expression at rest and after a bout of resistance exercise in young (18-30 yr) and old (80-89 yr) women. J Appl Physiol (1985). 2006; 101(1): 53-59.

[571] Ratkevicius A, Joyson A, Selmer I, et al. Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. J Gerontol A Biol Sci Med Sci. 2011; 66(6): 620-626.

[572] Welle S, Bhatt K, Shah B, Thornton C. Insulin-like growth factor-1 and myostatin mRNA expression in muscle: comparison between 62–77 and 21–31 yr old men. Exp Gerontol. 2002; 37(6): 833-839.

[573] Lee SJ. Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. J Clin Invest. 2021; 131(9): e148372.

[574] Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014; 157(6): 1279-1291.

[575] Bridgewood C, Russell T, Weedon H, et al. The novel cytokine Metrnl/IL-41 is elevated in Psoriatic Arthritis synovium and inducible from both entheseal and synovial fibroblasts. Clin Immunol. 2019; 208: 108253.

[576] Ushach I, Arrevillaga-Boni G, Heller GN, et al. Meteorin-like/meteorin-β is a novel immunoregulatory cytokine associated with inflammation. J Immunol. 2018; 201(12): 3669-3676.

[577] Ruas JL, White JP, Rao RR, et al. A PGC-1α isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell. 2012; 151(6): 1319-1331.

[578] Baht GS, Bareja A, Lee DE, et al. Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism. Nat Metab. 2020; 2(3): 278-289.

[579] Lee DE, McKay LK, Bareja A, et al. Meteorin-like is an injectable peptide that can enhance regeneration in aged muscle through immune-driven fibro/adipogenic progenitor signaling. Nat Commun. 2022; 13(1): 7613.

[580] Lee DE, McKay LK, Bareja A, et al. Meteorin-like is an injectable peptide that can enhance regeneration in aged muscle through immune-driven fibro/adipogenic progenitor signaling. Nat Commun. 2022; 13(1): 7613.

[581] Jung TW, Lee SH, Kim HC, et al. METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARδ-dependent pathways in skeletal muscle of mice. Exp Mol Med. 2018; 50(9): 1-11.

[582] Lee JO, Byun WS, Kang MJ, et al. The myokine meteorin-like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPKα2. FEBS J. 2020; 287(10): 2087-2104.

[583] Li ZY, Song J, Zheng SL, et al. Adipocyte Metrnl antagonizes insulin resistance through PPARγ signaling. Diabetes. 2015; 64(12): 4011-4022.

[584] Cai J, Wang QM, Li JW, et al. Serum Meteorin-like is associated with weight loss in the elderly patients with chronic heart failure. J Cachexia Sarcopenia Muscle. 2022; 13(1): 409-417.

[585] Roberts LD, Boström P, O’Sullivan JF, et al. β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab. 2014; 19(1): 96-108.

[586] Begriche K, Massart J, Abbey-Toby A, Igoudjil A, Lettéron P, Fromenty B. Beta-aminoisobutyric acid prevents diet-induced obesity in mice with partial leptin deficiency. Obesity (Silver Spring). 2008; 16(9): 2053-2067.

[587] Jung TW, Park HS, Choi GH, Kim D, Lee T. β-aminoisobutyric acid attenuates LPS-induced inflammation and insulin resistance in adipocytes through AMPK-mediated pathway. J Biomed Sci. 2018; 25(1): 27.

[588] Jung TW, Hwang HJ, Hong HC, Yoo HJ, Baik SH, Choi KM. BAIBA attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK-PPARδ-dependent pathway in mice. Diabetologia. 2015; 58(9): 2096-2105.

[589] Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008; 134(6): 933-944.

[590] Liu S, Brown JD, Stanya KJ, et al. A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use. Nature. 2013; 502(7472): 550-554.

[591] Stanford KI, Lynes MD, Takahashi H, et al. 12, 13-diHOME: an exercise-induced lipokine that increases skeletal muscle fatty acid uptake. Cell Metab. 2018; 27(5): 1111-1120. e3.

[592] Lynes MD, Leiria LO, Lundh M, et al. The cold-induced lipokine 12, 13-diHOME promotes fatty acid transport into brown adipose tissue. Nat Med. 2017; 23(5): 631-637.

[593] Shen CL, Ramamoorthy S, Kaur G, et al. Dietary annatto-extracted tocotrienol reduces inflammation and oxidative stress, and improves macronutrient metabolism in obese mice: a metabolic profiling study. Nutrients. 2021; 13(4): 1267.

[594] Wang T, He C, Yu X. Pro-inflammatory cytokines: new potential therapeutic targets for obesity-related bone disorders. Current drug targets. 2017; 18(14): 1664-1675.

[595] Bian AL, Hu HY, Rong YD, Wang J, Wang JX, Zhou XZ. A study on relationship between elderly sarcopenia and inflammatory factors IL-6 and TNF-α. Eur J Med Res. 2017; 22(1): 25.

[596] Wang Y, Welc SS, Wehling-Henricks M, Tidball JG. Myeloid cell-derived tumor necrosis factor-alpha promotes sarcopenia and regulates muscle cell fusion with aging muscle fibers. Aging Cell. 2018; 17(6): e12828.

[597] Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A. siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes. 2008; 57(8): 2066-2073.

[598] Varma V, Yao-Borengasser A, Rasouli N, et al. Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. Am J Physiol Endocrinol Metab. 2009; 296(6): E1300-E1310.

[599] Ciaraldi TP, Ryan AJ, Mudaliar SR, Henry RR. Altered myokine secretion is an intrinsic property of skeletal muscle in type 2 diabetes. PLoS One. 2016; 11(7): e0158209.

[600] Yang W, Hu P. Skeletal muscle regeneration is modulated by inflammation. J Orthop Translat. 2018; 13: 25-32.

[601] Chen SE, Gerken E, Zhang Y, et al. Role of TNF-{alpha} signaling in regeneration of cardiotoxin-injured muscle. Am J Physiol Cell Physiol. 2005; 289(5): C1179-C1187.

[602] Spencer MJ, Marino MW, Winckler WM. Altered pathological progression of diaphragm and quadriceps muscle in TNF-deficient, dystrophin-deficient mice. Neuromuscul Disord. 2000; 10(8): 612-619.

[603] Warren GL, Hulderman T, Jensen N, et al. Physiological role of tumor necrosis factor alpha in traumatic muscle injury. FASEB J. 2002; 16(12): 1630-1632.

[604] Fiore D, Judson RN, Low M, et al. Pharmacological blockage of fibro/adipogenic progenitor expansion and suppression of regenerative fibrogenesis is associated with impaired skeletal muscle regeneration. Stem Cell Res. 2016; 17(1): 161-169.

[605] Pagano AF, Arc-Chagnaud C, Brioche T, Chopard A, Py G. Muscle resting and TGF-β inhibitor treatment prevent fatty infiltration following skeletal muscle injury. Cell Physiol Biochem. 2019; 53(1): 62-75.

[606] Morin CL, Gayles EC, Podolin DA, Wei Y, Xu M, Pagliassotti MJ. Adipose tissue-derived tumor necrosis factor activity correlates with fat cell size but not insulin action in aging rats. Endocrinology. 1998; 139(12): 4998-5005.

[607] Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995; 95(5): 2111-2119.

[608] Hube F, Hauner H. The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res. 1999; 31(12): 626-631.

[609] Morin CL, Eckel RH, Marcel T, Pagliassotti MJ. High fat diets elevate adipose tissue-derived tumor necrosis factor-alpha activity. Endocrinology. 1997; 138(11): 4665-4671.

[610] Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997; 82(12): 4196-200.

[611] Patel HJ, Patel BM. TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci. 2017; 170: 56-63.

[612] Busquets S, Sanchís D, Alvarez B, Ricquier D, López-Soriano FJ, Argilés JM. In the rat, tumor necrosis factor alpha administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis? FEBS Lett. 1998; 440(3): 348-350.

[613] Schcolnik-Cabrera A, Chávez-Blanco A, Domínguez-Gómez G, Dueñas-González A. Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. Am J Cancer Res. 2017; 7(5): 1107-1135.

[614] Peterson JM, Feeback KD, Baas JH, Pizza FX. Tumor necrosis factor-alpha promotes the accumulation of neutrophils and macrophages in skeletal muscle. J Appl Physiol (1985). 2006; 101(5): 1394-1399.

[615] Chiba F, Soda K, Yamada S, et al. The importance of tissue environment surrounding the tumor on the development of cancer cachexia. Int J Oncol. 2014; 44(1): 177-186.

[616] Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020; 16(11): 654-667.

[617] Oost LJ, Kustermann M, Armani A, Blaauw B, Romanello V. Fibroblast growth factor 21 controls mitophagy and muscle mass. J Cachexia Sarcopenia Muscle. 2019; 10(3): 630-642.

[618] Conte M, Ostan R, Fabbri C, et al. Human aging and longevity are characterized by high levels of mitokines. J Gerontol A Biol Sci Med Sci. 2019; 74(5): 600-607.

[619] Bag Soytas R, Suzan V, Arman P, et al. Association of FGF-19 and FGF-21 levels with primary sarcopenia. Geriatr Gerontol Int. 2021; 21(10): 959-962.

[620] Roh E, Hwang SY, Yoo HJ, et al. Association of plasma FGF21 levels with muscle mass and muscle strength in a national multicentre cohort study: Korean Frailty and Aging Cohort Study. Age Ageing. 2021; 50(6): 1971-1978.

[621] Rosales-Soto G, Diaz-Vegas A, Casas M, Contreras-Ferrat A, Jaimovich E. Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers. J Mol Endocrinol. 2020.

[622] Xu Q, Lin S, Li Q, et al. Fibroblast growth factor 21 regulates lipid accumulation and adipogenesis in goat intramuscular adipocyte. Anim Biotechnol. 2021; 32(3): 318-326.

[623] Kim KH, Jeong YT, Oh H, et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med. 2013; 19(1): 83-92.

[624] Pereira RO, Tadinada SM, Zasadny FM, et al. OPA1 deficiency promotes secretion of FGF21 from muscle that prevents obesity and insulin resistance. EMBO J. 2017; 36(14): 2126-2145.

[625] Fisher FM, Kleiner S, Douris N, et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012; 26(3): 271-281.

[626] Wang Q, Yuan J, Yu Z, et al. FGF21 attenuates high-fat diet-induced cognitive impairment via metabolic regulation and anti-inflammation of obese mice. Mol Neurobiol. 2018; 55(6): 4702-4717.

[627] Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007; 148(2): 774-781.

[628] Talukdar S, Zhou Y, Li D, et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 2016; 23(3): 427-440.

[629] Stanislaus S, Hecht R, Yie J, et al. A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward β-klotho, and enhanced efficacy in mice and cynomolgus monkeys. Endocrinology. 2017; 158(5): 1314-1327.

[630] Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008; 57(5): 1246-1253.

[631] Chen C, Cheung BM, Tso AW, et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care. 2011; 34(9): 2113-2115.

[632] Xiao Y, Xu A, Law LS, et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab. 2012; 97(1): E54-E58.

[633] Lin Z, Tian H, Lam KS, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013; 17(5): 779-789.

[634] Wang YC, Li Y, Wang XY, et al. Circulating miR-130b mediates metabolic crosstalk between fat and muscle in overweight/obesity. Diabetologia. 2013; 56(10): 2275-2285.

[635] Criado-Mesas L, Ballester M, Crespo-Piazuelo D, et al. Expression analysis of porcine miR-33a/b in liver, adipose tissue and muscle and its potential role in fatty acid metabolism. PLoS One. 2021; 16(1): e0245858.

[636] Price NL, Singh AK, Rotllan N, et al. Genetic ablation of miR-33 increases food intake, enhances adipose tissue expansion, and promotes obesity and insulin resistance. Cell Rep. 2018; 22(8): 2133-2145.

[637] Li X, Qiu J, Liu H, et al. MicroRNA-33a negatively regulates myoblast proliferation by targeting IGF1, follistatin and cyclin D1. Biosci Rep. 2020; 40(6): BSR20191327.

[638] Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006; 38(2): 228-233.

[639] Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008; 22(23): 3242-3254.

[640] He B, Xiao J, Ren AJ, et al. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J Biomed Sci. 2011; 18(1): 22.

[641] Di Filippo ES, Mancinelli R, Pietrangelo T, et al. Myomir dysregulation and reactive oxygen species in aged human satellite cells. Biochem Biophys Res Commun. 2016; 473(2): 462-470.

[642] Nakasa T, Ishikawa M, Shi M, Shibuya H, Adachi N, Ochi M. Acceleration of muscle regeneration by local injection of muscle-specific microRNAs in rat skeletal muscle injury model. J Cell Mol Med. 2010; 14(10): 2495-2505.

[643] Iannone F, Montesanto A, Cione E, et al. Expression patterns of muscle-specific miR-133b and miR-206 correlate with nutritional status and sarcopenia. Nutrients. 2020; 12(2): 297.

[644] Drummond MJ, McCarthy JJ, Sinha M, et al. Aging and microRNA expression in human skeletal muscle: a microarray and bioinformatics analysis. Physiol Genomics. 2011; 43(10): 595-603.

[645] Chartoumpekis DV, Zaravinos A, Ziros PG, et al. Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice. PLoS One. 2012; 7(4): e34872.

[646] Yin H, Pasut A, Soleimani VD, et al. MicroRNA-133 controls brown adipose determination in skeletal muscle satellite cells by targeting Prdm16. Cell Metab. 2013; 17(2): 210-224.

[647] Gagan J, Dey BK, Layer R, Yan Z, Dutta A. Notch3 and Mef2c proteins are mutually antagonistic via Mkp1 protein and miR-1/206 microRNAs in differentiating myoblasts. J Biol Chem. 2012; 287(48): 40360-40370.

[648] Anderson C, Catoe H, Werner R. MIR-206 regulates connexin43 expression during skeletal muscle development. Nucleic Acids Res. 2006; 34(20): 5863-5871.

[649] Clop A, Marcq F, Takeda H, et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet. 2006; 38(7): 813-818.

[650] Chen JF, Tao Y, Li J, et al. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J Cell Biol. 2010; 190(5): 867-879.

[651] Jiang A, Dong C, Li B, et al. MicroRNA-206 regulates cell proliferation by targeting G6PD in skeletal muscle. FASEB J. 2019; 33(12): 14083-14094.

[652] Rusanova I, Fernández-Martínez J, Fernández-Ortiz M, et al. Involvement of plasma miRNAs, muscle miRNAs and mitochondrial miRNAs in the pathophysiology of frailty. Exp Gerontol. 2019; 124: 110637.

[653] Kim JY, Park YK, Lee KP, et al. Genome-wide profiling of the microRNA-mRNA regulatory network in skeletal muscle with aging. Aging (Albany NY). 2014; 6(7): 524-544.

[654] Hamrick MW, Herberg S, Arounleut P, et al. The adipokine leptin increases skeletal muscle mass and significantly alters skeletal muscle miRNA expression profile in aged mice. Biochem Biophys Res Commun. 2010; 400(3): 379-383.

[655] Drummond MJ, McCarthy JJ, Fry CS, Esser KA, Rasmussen BB. Aging differentially affects human skeletal muscle microRNA expression at rest and after an anabolic stimulus of resistance exercise and essential amino acids. Am J Physiol Endocrinol Metab. 2008; 295(6): E1333-E1340.

[656] Iacomino G, Russo P, Stillitano I, et al. Circulating microRNAs are deregulated in overweight/obese children: preliminary results of the I.Family study. Genes Nutr. 2016; 11: 7.

[657] Walden TB, Timmons JA, Keller P, Nedergaard J, Cannon B. Distinct expression of muscle-specific microRNAs (myomirs) in brown adipocytes. J Cell Physiol. 2009; 218(2): 444-449.

[658] Xu K, Ji M, Huang X, Peng Y, Wu W, Zhang J. Differential regulatory roles of MicroRNAs in porcine intramuscular and subcutaneous adipocytes. J Agric Food Chem. 2020; 68(13): 3954-3962.

[659] Connolly M, Garfield BE, Crosby A, Morrell NW, Wort SJ, Kemp PR. miR-322-5p targets IGF-1 and is suppressed in the heart of rats with pulmonary hypertension. FEBS Open Bio. 2018; 8(3): 339-348.

[660] Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A, Giorgino F. The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol. 2010; 205(3): 201-210.

[661] Connolly M, Paul R, Farre-Garros R, et al. miR-424-5p reduces ribosomal RNA and protein synthesis in muscle wasting. J Cachexia Sarcopenia Muscle. 2018; 9(2): 400-416.

[662] Munkhzul C, Lee JM, Kim B, et al. H19X-encoded microRNAs induced by IL-4 in adipocyte precursors regulate proliferation to facilitate differentiation. Biol Direct. 2023; 18(1): 32.

[663] Gasparotto AS, Borges DO, Sassi MGM, et al. Differential expression of miRNAs related to angiogenesis and adipogenesis in subcutaneous fat of obese and nonobese women. Mol Biol Rep. 2019; 46(1): 965-973.

[664] Dey BK, Pfeifer K, Dutta A. The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration. Genes Dev. 2014; 28(5): 491-501.

[665] Kallen AN, Zhou XB, Xu J, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell. 2013; 52(1): 101-112.

[666] Qin CY, Cai H, Qing HR, Li L, Zhang HP. Recent advances on the role of long non-coding RNA H19 in regulating mammalian muscle growth and development. Yi Chuan. 2017; 39(12): 1150-1157.

[667] Zhang BF, Chen J, Jiang H. LncRNA H19 ameliorates myocardial ischemia-reperfusion injury by targeting miR-22-3P. Int J Cardiol. 2019; 278: 224.

[668] Li Y, Zhang Y, Hu Q, et al. Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects. Genome Med. 2021; 13(1): 137.

[669] Luan W, Zhou Z, Ni X, et al. Long non-coding RNA H19 promotes glucose metabolism and cell growth in malignant melanoma via miR-106a-5p/E2F3 axis. J Cancer Res Clin Oncol. 2018; 144(3): 531-542.

[670] Gao Y, Wu F, Zhou J, et al. The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cells. Nucleic Acids Res. 2014; 42(22): 13799-13811.

[671] Gui W, Zhu WF, Zhu Y, et al. LncRNAH19 improves insulin resistance in skeletal muscle by regulating heterogeneous nuclear ribonucleoprotein A1. Cell Commun Signal. 2020; 18(1): 173.

[672] Watts R, Johnsen VL, Shearer J, Hittel DS. Myostatin-induced inhibition of the long noncoding RNA Malat1 is associated with decreased myogenesis. Am J Physiol Cell Physiol. 2013; 304(10): C995-C1001.

[673] Ruan L, Mendhe B, Parker E, et al. Long non-coding RNA MALAT1 is depleted with age in skeletal muscle in vivo and MALAT1 silencing increases expression of TGF-β1 in vitro. Front Physiol. 2021; 12: 742004.

[674] Han X, Yang F, Cao H, Liang Z. Malat1 regulates serum response factor through miR-133 as a competing endogenous RNA in myogenesis. FASEB J. 2015; 29(7): 3054-3064.

[675] Chen X, He L, Zhao Y, et al. Malat1 regulates myogenic differentiation and muscle regeneration through modulating MyoD transcriptional activity. Cell Discov. 2017; 3: 17002.

[676] Han J, Shen L, Zhan Z, et al. The long noncoding RNA MALAT1 modulates adipose loss in cancer-associated cachexia by suppressing adipogenesis through PPAR-γ. Nutr Metab. 2021; 18(1): 27.

[677] Gao J, Li X, Wang Y, et al. Adipocyte-derived extracellular vesicles modulate appetite and weight through mTOR signalling in the hypothalamus. Acta Physiolog (Oxford, England). 2020; 228(2): e13339.

[678] Matsuo Y, Gleitsmann K, Mangner N, et al. Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure-relevance of inflammatory cytokines. J Cachexia Sarcopenia Muscle. 2015; 6(1): 62-72.

[679] Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Investig. 1997; 100(11): 2777-2782.

[680] Zhang HH, Kumar S, Barnett AH, Eggo MC. Tumour necrosis factor-alpha exerts dual effects on human adipose leptin synthesis and release. Mol Cell Endocrinol. 2000; 159(1-2): 79-88.

[681] Yamaguchi M, Murakami T, Tomimatsu T, et al. Autocrine inhibition of leptin production by tumor necrosis factor-alpha (TNF-alpha) through TNF-alpha type-I receptor in vitro. Biochem Biophys Res Commun. 1998; 244(1): 30-34.

[682] Rodríguez A, Becerril S, Méndez-Giménez L, et al. Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice. Int J Obes. 2015; 39(3): 397-407.

[683] Frühbeck G, Sesma P, Burrell MA. PRDM16: the interconvertible adipo-myocyte switch. Trends Cell Biol. 2009; 19(4): 141-146.

[684] Becerril S, Gómez-Ambrosi J, Martín M, et al. Role of PRDM16 in the activation of brown fat programming. Relevance to the development of obesity. Histol Histopathol. 2013; 28(11): 1411-1425.

[685] Cohen P, Levy JD, Zhang Y, et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell. 2014; 156(1-2): 304-316.

[686] Choi SJ, Yablonka-Reuveni Z, Kaiyala KJ, Ogimoto K, Schwartz MW, Wisse BE. Increased energy expenditure and leptin sensitivity account for low fat mass in myostatin-deficient mice. Am J Physiol Endocrinol Metab. 2011; 300(6): E1031-E1037.

[687] Sannicandro AJ, Soriano-Arroquia A, Goljanek-Whysall K. Micro(RNA)-managing muscle wasting. J Appl Physiol (1985). 2019; 127(2): 619-632.

[688] Kita S, Maeda N, Shimomura I. Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome. J Clin Invest. 2019; 129(10): 4041-4049.

[689] Vechetti IJ, Jr., Peck BD, Wen Y, et al. Mechanical overload-induced muscle-derived extracellular vesicles promote adipose tissue lipolysis. FASEB J. 2021; 35(6): e21644.

[690] Dowling L, Duseja A, Vilaca T, Walsh JS, Goljanek-Whysall K. MicroRNAs in obesity, sarcopenia, and commonalities for sarcopenic obesity: a systematic review. J Cachexia Sarcopenia Muscle. 2022; 13(1): 68-85.

[691] Saccone V, Consalvi S, Giordani L, et al. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles. Genes Dev. 2014; 28(8): 841-857.

[692] Clark MB, Amaral PP, Schlesinger FJ, et al. The reality of pervasive transcription. PLoS Biol. 2011; 9(7):e1000625; discussion e1001102.

[693] Wijesinghe SN, Nicholson T, Tsintzas K, Jones SW. Involvements of long noncoding RNAs in obesity-associated inflammatory diseases. Obes Rev. 2021; 22(4): e13156.

[694] Wilhelmsen A, Tsintzas K, Jones SW. Recent advances and future avenues in understanding the role of adipose tissue cross talk in mediating skeletal muscle mass and function with ageing. Geroscience. 2021; 43(1): 85-110.

[695] Gingrich A, Volkert D, Kiesswetter E, et al. Prevalence and overlap of sarcopenia, frailty, cachexia and malnutrition in older medical inpatients. BMC Geriatr. 2019; 19(1): 120.

[696] Zopf Y, Schink K, Reljic D, et al. Assessing cachexia in older patients: Different definitions - But which one is the most practical for clinical routine? Arch Gerontol Geriatr. 2020; 86: 103943.

[697] Buentzel J, Heinz J, Bleckmann A, et al. Sarcopenia as prognostic factor in lung cancer patients: a systematic review and meta-analysis. Anticancer Res. 2019; 39(9): 4603-4612.

[698] Peterson SJ, Mozer M. Differentiating sarcopenia and cachexia among patients with cancer. Nutr Clin Pract. 2017; 32(1): 30-39.

[699] Jensen GL, Cederholm T. The malnutrition overlap syndromes of cachexia and sarcopenia: a malnutrition conundrum. Am J Clin Nutr. 2018; 108(6): 1157-1158.

[700] Bullock AF, Greenley SL, McKenzie GAG, Paton LW, Johnson MJ. Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis. Eur J Clin Nutr. 2020; 74(11): 1519-1535.

[701] Miller J, Wells L, Nwulu U, Currow D, Johnson MJ, Skipworth RJE. Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: a systematic review. Am J Clin Nutr. 2018; 108(6): 1196-1208.

[702] Dunne RF, Loh KP, Williams GR, Jatoi A, Mustian KM, Mohile SG. Cachexia and sarcopenia in older adults with cancer: a comprehensive review. Cancers (Basel). 2019; 11(12): 1861.

[703] Delmonico MJ, Harris TB, Lee JS, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc. 2007; 55(5): 769-774.

[704] Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006; 61(10): 1059-1064.

[705] Arai H, Maeda K, Wakabayashi H, et al. Diagnosis and outcomes of cachexia in Asia: Working Consensus Report from the Asian Working Group for Cachexia. J Cachexia Sarcopenia Muscle. 2023; 14(5): 1949-1958.

[706] Argilés JM, Anker SD, Evans WJ, et al. Consensus on cachexia definitions. J Am Med Dir Assoc. 2010; 11(4): 229-230.

[707] Heymsfield SB, Adamek M, Gonzalez MC, Jia G, Thomas DM. Assessing skeletal muscle mass: historical overview and state of the art. J Cachexia Sarcopenia Muscle. 2014; 5(1): 9-18.

[708] Chien MY, Huang TY, Wu YT. Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan. J Am Geriatr Soc. 2008; 56(9): 1710-1715.

[709] Scharf G, Heineke J. Finding good biomarkers for sarcopenia. J Cachexia Sarcopenia Muscle. 2012; 3(3): 145-148.

[710] Cesari M, Fielding RA, Pahor M, et al. Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle. 2012; 3(3): 181-190.

[711] Bioelectrical impedance analysis in body composition measurement: National Institutes of Health Technology Assessment Conference Statement. Am J Clin Nutr. 1996; 64(3 Suppl): 524s-532s.

[712] Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol (1985). 2000; 89(2): 465-471.

[713] Roubenoff R, Baumgartner RN, Harris TB, et al. Application of bioelectrical impedance analysis to elderly populations. J Gerontol A Biol Sci Med Sci. 1997; 52(3): M129-M136.

[714] Kyle UG, Genton L, Karsegard L, Slosman DO, Pichard C. Single prediction equation for bioelectrical impedance analysis in adults aged 20–94 years. Nutrition. 2001; 17(3): 248-253.

[715] Functional outcomes for clinical trials in frail older persons: time to be moving. J Gerontol A Biol Sci Med Sci. 2008; 63(2): 160-164.

[716] Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005; 90(5): 2920-2926.

[717] Laviano A, Gleason JR, Meguid MM, Yang ZJ, Cangiano C, Rossi Fanelli F. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Investig Med. 2000; 48(1): 40-48.

[718] Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89(6): 2832-2836.

[719] Lacquaniti A, Donato V, Chirico V, Buemi A, Buemi M. Obestatin: an interesting but controversial gut hormone. Ann Nutr Metab. 2011; 59(2-4): 193-199.

[720] Mondello P, Lacquaniti A, Mondello S, et al. Emerging markers of cachexia predict survival in cancer patients. BMC Cancer. 2014; 14: 828.

[721] Drescher C, Konishi M, Ebner N, Springer J. Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment. Int J Cardiol. 2016; 202: 766-772.

[722] Drescher C, Konishi M, Ebner N, Springer J. Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment. J Cachexia Sarcopenia Muscle. 2015; 6(4): 303-311.

[723] Fujiwara Y, Kobayashi T, Chayahara N, et al. Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. PLoS One. 2014; 9(11): e113259.

[724] Bye A, Wesseltoft-Rao N, Iversen PO, et al. Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer. Med Oncol. 2016; 33(6): 54.

[725] Stanford KI, Middelbeek RJ, Townsend KL, et al. A novel role for subcutaneous adipose tissue in exercise-induced improvements in glucose homeostasis. Diabetes. 2015; 64(6): 2002-2014.

[726] Trevellin E, Scorzeto M, Olivieri M, et al. Exercise training induces mitochondrial biogenesis and glucose uptake in subcutaneous adipose tissue through eNOS-dependent mechanisms. Diabetes. 2014; 63(8): 2800-2811.

[727] Zachwieja JJ, Hendry SL, Smith SR, Harris RB. Voluntary wheel running decreases adipose tissue mass and expression of leptin mRNA in Osborne-Mendel rats. Diabetes. 1997; 46(7): 1159-1166.

[728] Dewal RS, Stanford KI. Effects of exercise on brown and beige adipocytes. Biochim Biophys Acta Mol Cell Biol Lipids. 2019; 1864(1): 71-78.

[729] Félix-Soriano E, Sáinz N, Gil-Iturbe E, et al. Differential remodeling of subcutaneous white and interscapular brown adipose tissue by long-term exercise training in aged obese female mice. J Physiol Biochem. 2023; 79(2): 451-465.

[730] Justice JN, Gregory H, Tchkonia T, et al. Cellular senescence biomarker p16INK4a+ cell burden in thigh adipose is associated with poor physical function in older women. J Gerontol A Biol Sci Med Sci. 2018; 73(7): 939-945.

[731] Thirupathi A, da Silva Pieri BL, Queiroz J, et al. Strength training and aerobic exercise alter mitochondrial parameters in brown adipose tissue and equally reduce body adiposity in aged rats. J Physiol Biochem. 2019; 75(1): 101-108.

[732] Angulo J, El Assar M, Álvarez-Bustos A, Rodríguez-Mañas L. Physical activity and exercise: strategies to manage frailty. Redox Biol. 2020; 35: 101513.

[733] Aldiss P, Betts J, Sale C, Pope M, Budge H, Symonds ME. Exercise-induced ‘browning’ of adipose tissues. Metabolism. 2018; 81: 63-70.

[734] Wu F, Li Z, Cai M, et al. Aerobic exercise alleviates oxidative stress-induced apoptosis in kidneys of myocardial infarction mice by inhibiting ALCAT1 and activating FNDC5/Irisin signaling pathway. Free Radic Biol Med. 2020; 158: 171-180.

[735] Vikberg S, Sörlén N, Brandén L, et al. Effects of resistance training on functional strength and muscle mass in 70-year-old individuals with pre-sarcopenia: a randomized controlled trial. J Am Med Dir Assoc. 2019; 20(1): 28-34.

[736] Gonzalez AM, Hoffman JR, Stout JR, Fukuda DH, Willoughby DS. Intramuscular anabolic signaling and endocrine response following resistance exercise: implications for muscle hypertrophy. Sports Med. 2016; 46(5): 671-685.

[737] Ziaaldini MM, Koltai E, Csende Z, et al. Exercise training increases anabolic and attenuates catabolic and apoptotic processes in aged skeletal muscle of male rats. Exp Gerontol. 2015; 67: 9-14.

[738] Tromm CB, Pozzi BG, Paganini CS, et al. The role of continuous versus fractionated physical training on muscle oxidative stress parameters and calcium-handling proteins in aged rats. Aging Clin Exp Res. 2016; 28(5): 833-841.

[739] Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab Care. 2004; 7(4): 405-410.

[740] Nascimento CM, Ingles M, Salvador-Pascual A, Cominetti MR, Gomez-Cabrera MC, Viña J. Sarcopenia, frailty and their prevention by exercise. Free Radic Biol Med. 2019; 132: 42-49.

[741] Lake DA. Neuromuscular electrical stimulation. An overview and its application in the treatment of sports injuries. Sports Med. 1992; 13(5): 320-336.

[742] Cabric M, Appell HJ, Resic A. Effects of electrical stimulation of different frequencies on the myonuclei and fiber size in human muscle. Int J Sports Med. 1987; 8(5): 323-326.

[743] Almeida GJ, Khoja SS, Piva SR. Dose-response relationship between neuromuscular electrical stimulation and muscle function in people with rheumatoid arthritis. Phys Ther. 2019; 99(9): 1167-1176.

[744] Paillard T, Noe F, Bernard N, Dupui P, Hazard C. Effects of two types of neuromuscular electrical stimulation training on vertical jump performance. J Strength Cond Res. 2008; 22(4): 1273-1278.

[745] Gondin J, Guette M, Ballay Y, Martin A. Electromyostimulation training effects on neural drive and muscle architecture. Med Sci Sports Exerc. 2005; 37(8): 1291-1299.

[746] Kim CK, Takala TE, Seger J, Karpakka J. Training effects of electrically induced dynamic contractions in human quadriceps muscle. Aviat Space Environ Med. 1995; 66(3): 251-255.

[747] Pette D, Vrbová G. The contribution of neuromuscular stimulation in elucidating muscle plasticity revisited. Eur J Transl Myol. 2017; 27(1): 6368.

[748] Hainaut K, Duchateau J. Neuromuscular electrical stimulation and voluntary exercise. Sports Med. 1992; 14(2): 100-113.

[749] Boutry-Regard C, Vinyes-Parés G, Breuillé D, Moritani T. Supplementation with whey protein, omega-3 fatty acids and polyphenols combined with electrical muscle stimulation increases muscle strength in elderly adults with limited mobility: a randomized controlled trial. Nutrients. 2020; 12(6): 1866.

[750] Paillard T. Relationship between muscle function, muscle typology and postural performance according to different postural conditions in young and older adults. Front Physiol. 2017; 8: 585.

[751] Kern H, Barberi L, Löfler S, et al. Electrical stimulation counteracts muscle decline in seniors. Front Aging Neurosci. 2014; 6: 189.

[752] Paillard T. Muscle plasticity of aged subjects in response to electrical stimulation training and inversion and/or limitation of the sarcopenic process. Ageing Res Rev. 2018; 46: 1-13.

[753] Mattson MP, Longo VD, Harvie M. Impact of intermittent fasting on health and disease processes. Ageing Res Rev. 2017; 39: 46-58.

[754] de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019; 381(26): 2541-2551.

[755] Golbidi S, Daiber A, Korac B, Li H, Essop MF, Laher I. Health benefits of fasting and caloric restriction. Curr Diab Rep. 2017; 17(12): 123.

[756] Li G, Xie C, Lu S, et al. Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota. Cell Metab. 2017; 26(4): 672-685. e4.

[757] Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab. 2018; 27(6): 1212-1221. e3.

[758] Jamshed H, Beyl RA, Della Manna DL, Yang ES, Ravussin E, Peterson CM. Early time-restricted feeding improves 24-hour glucose levels and affects markers of the circadian clock, aging, and autophagy in humans. Nutrients. 2019; 11(6): 1234.

[759] Carnio S, LoVerso F, Baraibar MA, et al. Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging. Cell Rep. 2014; 8(5): 1509-1521.

[760] Franco-Romero A, Sandri M. Role of autophagy in muscle disease. Mol Aspects Med. 2021; 82: 101041.

[761] Johnson JB, Summer W, Cutler RG, et al. Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free Radic Biol Med. 2007; 42(5): 665-674.

[762] Harvie M, Wright C, Pegington M, et al. The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. Br J Nutr. 2013; 110(8): 1534-1547.

[763] Miller KN, Burhans MS, Clark JP, et al. Aging and caloric restriction impact adipose tissue, adiponectin, and circulating lipids. Aging Cell. 2017; 16(3): 497-507.

[764] Sheng Y, Xia F, Chen L, et al. Differential responses of white adipose tissue and brown adipose tissue to calorie restriction during aging. J Gerontol A Biol Sci Med Sci. 2021; 76(3): 393-399.

[765] Fabbiano S, Suarez-Zamorano N, Rigo D, et al. Caloric restriction leads to browning of white adipose tissue through type 2 immune signaling. Cell Metab. 2016; 24(3): 434-446.

[766] Toledo FG, Menshikova EV, Ritov VB, et al. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. Diabetes. 2007; 56(8): 2142-2147.

[767] Boldrin L, Ross JA, Whitmore C, et al. The effect of calorie restriction on mouse skeletal muscle is sex, strain and time-dependent. Sci Rep. 2017; 7(1): 5160.

[768] Ross SA, Ryan DS, Dominguez S, Nigam N, Wakeling JM. Size, history-dependent, activation and three-dimensional effects on the work and power produced during cyclic muscle contractions. Integr Comp Biol. 2018; 58(2): 232-250.

[769] Rhoads TW, Clark JP, Gustafson GE, et al. Molecular and functional networks linked to sarcopenia prevention by caloric restriction in rhesus monkeys. Cell Syst. 2020; 10(2): 156-168. e5.

[770] Bevilacqua L, Ramsey JJ, Hagopian K, Weindruch R, Harper ME. Effects of short-and medium-term calorie restriction on muscle mitochondrial proton leak and reactive oxygen species production. Am J Physiol Endocrinol Metab. 2004; 286(5): E852-E861.

[771] Marzetti E, Lawler JM, Hiona A, Manini T, Seo AY, Leeuwenburgh C. Modulation of age-induced apoptotic signaling and cellular remodeling by exercise and calorie restriction in skeletal muscle. Free Radic Biol Med. 2008; 44(2): 160-168.

[772] Dirks Naylor AJ, Leeuwenburgh C. Sarcopenia: the role of apoptosis and modulation by caloric restriction. Exerc Sport Sci Rev. 2008; 36(1): 19-24.

[773] Dirks AJ, Leeuwenburgh C. Aging and lifelong calorie restriction result in adaptations of skeletal muscle apoptosis repressor, apoptosis-inducing factor, X-linked inhibitor of apoptosis, caspase-3, and caspase-12. Free Radic Biol Med. 2004; 36(1): 27-39.

[774] Speakman JR, Mitchell SE. Caloric restriction. Mol Aspects Med. 2011; 32(3): 159-221.

[775] Monnard CR, Dulloo AG. Polyunsaturated fatty acids as modulators of fat mass and lean mass in human body composition regulation and cardiometabolic health. Obes Rev. 2021; 22(Suppl 2):e13197.

[776] Bender N, Portmann M, Heg Z, Hofmann K, Zwahlen M, Egger M. Fish or n3-PUFA intake and body composition: a systematic review and meta-analysis. Obes Rev. 2014; 15(8): 657-665.

[777] Hames KC, Morgan-Bathke M, Harteneck DA, et al. Very-long-chain ω-3 fatty acid supplements and adipose tissue functions: a randomized controlled trial. Am J Clin Nutr. 2017; 105(6): 1552-1558.

[778] Wu JHY, Marklund M, Imamura F, et al. Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies. Lancet Diabetes Endocrinol. 2017; 5(12): 965-974.

[779] Forouhi NG, Imamura F, Sharp SJ, et al. Association of plasma phospholipid n-3 and n-6 polyunsaturated fatty acids with type 2 diabetes: The EPIC-InterAct Case-Cohort Study. PLoS Med. 2016; 13(7): e1002094.

[780] Belury MA, Cole RM, Bailey BE, Ke JY, Andridge RR, Kiecolt-Glaser JK. Erythrocyte linoleic acid, but not oleic acid, is associated with improvements in body composition in men and women. Mol Nutr Food Res. 2016; 60(5): 1206-1212.

[781] Yepuri G, Marcelino H, Shahkhalili Y, et al. Dietary modulation of body composition and insulin sensitivity during catch-up growth in rats: effects of oils rich in n-6 or n-3 PUFA. Br J Nutr. 2011; 105(12): 1750-1763.

[782] Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992; 339(8808): 1523-1526.

[783] Zhao Y, Chen B, Shen J, et al. The beneficial effects of quercetin, curcumin, and resveratrol in obesity. Oxid Med Cell Longev. 2017; 2017: 1459497.

[784] Aguirre L, Fernandez-Quintela A, Arias N, Portillo MP. Resveratrol: anti-obesity mechanisms of action. Molecules. 2014; 19(11): 18632-18655.

[785] Springer M, Moco S. Resveratrol and its human metabolites-effects on metabolic health and obesity. Nutrients. 2019; 11(1): 143.

[786] Huang Y, Zhu X, Chen K, et al. Resveratrol prevents sarcopenic obesity by reversing mitochondrial dysfunction and oxidative stress via the PKA/LKB1/AMPK pathway. Aging (Albany NY). 2019; 11(8): 2217-2240.

[787] Fernandez-Quintela A, Milton-Laskibar I, Gonzalez M, Portillo MP. Antiobesity effects of resveratrol: which tissues are involved? Ann N Y Acad Sci. 2017; 1403(1): 118-131.

[788] Toniolo L, Formoso L, Torelli L, et al. Long-term resveratrol treatment improves the capillarization in the skeletal muscles of ageing C57BL/6J mice. Int J Food Sci Nutr. 2021; 72(1): 37-44.

[789] Brandt N, Nielsen L, Thiellesen Buch B, et al. Impact of β-adrenergic signaling in PGC-1α-mediated adaptations in mouse skeletal muscle. Am J Physiol Endocrinol Metab. 2018; 314(1): E1-E20.

[790] Kwak JY, Kwon KS. Pharmacological interventions for treatment of sarcopenia: current status of drug development for sarcopenia. Ann Geriatr Med Res. 2019; 23(3): 98-104.

[791] Bahat G, Ozkok S. The current landscape of pharmacotherapies for sarcopenia. Drugs Aging. 2024; 41(2): 83-112.

[792] Hardee JP, Lynch GS. Current pharmacotherapies for sarcopenia. Expert Opin Pharmacother. 2019; 20(13): 1645-1657.

[793] Sakuma K, Hamada K, Yamaguchi A, Aoi W. Current nutritional and pharmacological approaches for attenuating sarcopenia. Cells. 2023; 12(19): 2422.

[794] Najm A, Niculescu AG, Grumezescu AM, Beuran M. Emerging therapeutic strategies in sarcopenia: an updated review on pathogenesis and treatment advances. Int J Mol Sci. 2024; 25(8): 4300.

[795] Breining P, Jensen JB, Sundelin EI, et al. Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro. Diabetes Obes Metab. 2018; 20(9): 2264-2273.

[796] Kulkarni AS, Brutsaert EF, Anghel V, et al. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. Aging Cell. 2018; 17(2): e12723.

[797] Guzzoni V, Ribeiro MBT, Lopes GN, et al. Effect of resistance training on extracellular matrix adaptations in skeletal muscle of older rats. Front Physiol. 2018; 9: 374.

[798] Song Y, Wu Z, Zhao P. The function of metformin in aging-related musculoskeletal disorders. Front Pharmacol. 2022; 13: 865524.

[799] Laksmi PW, Setiati S, Tamin TZ, et al. Effect of metformin on handgrip strength, gait speed, myostatin serum level, and health-related quality of life: a double blind randomized controlled trial among non-diabetic pre-frail elderly patients. Acta Med Indones. 2017; 49(2): 118-127.

[800] Sexton P, Metcalf P, Kolbe J. Respiratory effects of insulin sensitisation with metformin: a prospective observational study. Copd. 2014; 11(2): 133-142.

[801] Bautista DM, Siemens J, Glazer JM, et al. The menthol receptor TRPM8 is the principal detector of environmental cold. Nature. 2007; 448(7150): 204-208.

[802] Li C, Li J, Xiong X, et al. TRPM8 activation improves energy expenditure in skeletal muscle and exercise endurance in mice. Gene. 2018; 641: 111-116.

[803] Chernogubova E, Cannon B, Bengtsson T. Norepinephrine increases glucose transport in brown adipocytes via beta3-adrenoceptors through a cAMP, PKA, and PI3-kinase-dependent pathway stimulating conventional and novel PKCs. Endocrinology. 2004; 145(1): 269-280.

[804] Zhao J, Unelius L, Bengtsson T, Cannon B, Nedergaard J. Coexisting beta-adrenoceptor subtypes: significance for thermogenic process in brown fat cells. Am J Physiol. 1994; 267(4 Pt 1): C969-C979.

[805] Warner A, Kjellstedt A, Carreras A, et al. Activation of β3-adrenoceptors increases in vivo free fatty acid uptake and utilization in brown but not white fat depots in high-fat-fed rats. Am J Physiol Endocrinol Metab. 2016; 311(6): E901-E910.

[806] Finlin BS, Memetimin H, Confides AL, et al. Human adipose beiging in response to cold and mirabegron. JCI Insight. 2018; 3(15): e12510.

[807] Tavernier G, Barbe P, Galitzky J, et al. Expression of beta3-adrenoceptors with low lipolytic action in human subcutaneous white adipocytes. J Lipid Res. 1996; 37(1): 87-97.

[808] Blondin DP, Nielsen S, Kuipers EN, et al. Human brown adipocyte thermogenesis is driven by β2-AR stimulation. Cell Metab. 2020; 32(2): 287-300. e7.

[809] Joassard OR, Durieux AC, Freyssenet DG. β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders. Int J Biochem Cell Biol. 2013; 45(10): 2309-2321.

[810] Zeman RJ, Ludemann R, Easton TG, Etlinger JD. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist. Am J Physiol. 1988; 254(6 Pt 1): E726-E732.

[811] Rajab P, Fox J, Riaz S, Tomlinson D, Ball D, Greenhaff PL. Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am J Physiol Regul Integr Comp Physiol. 2000; 279(3): R1076-R1081.

[812] Kim J, Grotegut CA, Wisler JW, et al. The β-arrestin-biased β-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility. Proc Natl Acad Sci U S A. 2020; 117(22): 12435-12443.

[813] Schertzer JD, Plant DR, Ryall JG, Beitzel F, Stupka N, Lynch GS. Beta2-agonist administration increases sarcoplasmic reticulum Ca2+-ATPase activity in aged rat skeletal muscle. Am J Physiol Endocrinol Metab. 2005; 288(3): E526-E533.

[814] Wei L, Gregorich ZR, Lin Z, et al. Novel sarcopenia-related alterations in sarcomeric protein post-translational modifications (PTMs) in skeletal muscles identified by top-down proteomics. Mol Cell Proteomics. 2018; 17(1): 134-145.

[815] Larsson L, Ramamurthy B. Aging-related changes in skeletal muscle. Mechanisms and interventions. Drugs Aging. 2000; 17(4): 303-316.

[816] Jiang GL, Gu YD, Zhang LY, Shen LY, Yu C, Xu JG. Randomized, double-blind, and placebo-controlled trial of clenbuterol in denervated muscle atrophy. ISRN Pharm. 2011; 2011: 981254.

[817] Ryall JG, Schertzer JD, Alabakis TM, Gehrig SM, Plant DR, Lynch GS. Intramuscular beta2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury. J Appl Physiol (1985). 2008; 105(1): 165-172.

[818] Beitzel F, Gregorevic P, Ryall JG, Plant DR, Sillence MN, Lynch GS. Beta2-adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. J Appl Physiol (1985). 2004; 96(4): 1385-1392.

[819] Sato M, Dehvari N, Oberg AI, et al. Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes. 2014; 63(12): 4115-4129.

[820] Finlin BS, Memetimin H, Zhu B, et al. The β3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans. J Clin Invest. 2020; 130(5): 2319-2331.

[821] Suntar I, Sureda A, Belwal T, et al. Natural products, PGC-1 α and Duchenne muscular dystrophy. Acta Pharm Sin B. 2020; 10(5): 734-745.

[822] Takeda K, Sawazaki H, Takahashi H, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice. FEBS Open Bio. 2018; 8(11): 1782-1793.

[823] Beiroa D, Imbernon M, Gallego R, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014; 63(10): 3346-3358.

[824] Gunton JE, Cheung NW, Davis TM, Zoungas S, Colagiuri S. A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society. Med J Aust. 2014; 201(11): 650-653.

[825] Wang T, Yang L, Liang Z, et al. Targeting cellular senescence prevents glucocorticoid-induced bone loss through modulation of the DPP4-GLP-1 axis. Signal Transduct Target Ther. 2021; 6(1): 143.

[826] Sato H, Kubota N, Kubota T, et al. Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice. Diabetologia. 2016; 59(11): 2426-2434.

[827] Kooijman S, Wang Y, Parlevliet ET, et al. Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice. Diabetologia. 2015; 58(11): 2637-2646.

[828] Nahon KJ, Doornink F, Straat ME, et al. Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial. Diabetologia. 2018; 61(11): 2386-2397.

[829] Bouchi R, Fukuda T, Takeuchi T, et al. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. Diabetes Metab Res Rev. 2018; 34(2).

[830] Rizzo MR, Barbieri M, Fava I, et al. Sarcopenia in elderly diabetic patients: role of dipeptidyl peptidase 4 inhibitors. J Am Med Dir Assoc. 2016; 17(10): 896-901.

[831] Yajima T, Yajima K, Takahashi H, Yasuda K. The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis. J Diabetes Complications. 2018; 32(8): 759-763.

[832] Perna S, Guido D, Bologna C, et al. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res. 2016; 28(6): 1251-1257.

[833] Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020; 173(4): 278-286.

[834] Baker DJ, Perez-Terzic C, Jin F, et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol. 2008; 10(7): 825-836.

[835] Sang Y, Zhang F, Wang H, et al. Apigenin exhibits protective effects in a mouse model of d-galactose-induced aging via activating the Nrf2 pathway. Food Funct. 2017; 8(6): 2331-2340.

[836] Villaret A, Galitzky J, Decaunes P, et al. Adipose tissue endothelial cells from obese human subjects: differences among depots in angiogenic, metabolic, and inflammatory gene expression and cellular senescence. Diabetes. 2010; 59(11): 2755-2763.

[837] Espinosa De Ycaza AE, Søndergaard E, Morgan-Bathke M, et al. Senescent cells in human adipose tissue: a cross-sectional study. Obesity (Silver Spring). 2021; 29(8): 1320-1327.

[838] Greene MA, Loeser RF. Aging-related inflammation in osteoarthritis. Osteoarthritis Cartilage. 2015; 23(11): 1966-1971.

[839] Ambrosi TH, Marecic O, McArdle A, et al. Aged skeletal stem cells generate an inflammatory degenerative niche. Nature. 2021; 597(7875): 256-262.

[840] Palmer AK, Xu M, Zhu Y, et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell. 2019; 18(3): e12950.

[841] Wang T, Huang S, He C. Senescent cells: A therapeutic target for osteoporosis. Cell Prolif. 2022:e13323.

[842] Wang T, Yang L, Liang Z, et al. Pulsed electromagnetic fields attenuate glucocorticoid-induced bone loss by targeting senescent LepR(+) bone marrow mesenchymal stromal cells. Biomater Adv. 2022; 133: 112635.

[843] Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011; 479(7372): 232-236.

[844] Chen QN, Fan Z, Lyu AK, et al. Effect of sarcolipin-mediated cell transdifferentiation in sarcopenia-associated skeletal muscle fibrosis. Exp Cell Res. 2020; 389(1): 111890.

[845] Sousa-Victor P, Gutarra S, Garcia-Prat L, et al. Geriatric muscle stem cells switch reversible quiescence into senescence. Nature. 2014; 506(7488): 316-321.

[846] Frikke-Schmidt H, O’Rourke RW, Lumeng CN, Sandoval DA, Seeley RJ. Does bariatric surgery improve adipose tissue function? Obes Rev. 2016; 17(9): 795-809.

[847] Sinclair P, Docherty N, le Roux CW. Metabolic effects of bariatric surgery. Clin Chem. 2018; 64(1): 72-81.

[848] Cogollo VJ, Rivera CE, Valera RJ, et al. Improvement of glucose metabolism following rapid weight loss after bariatric surgery and its impact on reduction of visceral abdominal fat versus free fat muscle. Surg Obes Relat Dis. 2021; 17(5): 933-938.

[849] Toro-Ramos T, Goodpaster BH, Janumala I, et al. Continued loss in visceral and intermuscular adipose tissue in weight-stable women following bariatric surgery. Obesity (Silver Spring). 2015; 23(1): 62-69.

[850] Nuijten MAH, Eijsvogels TMH, Monpellier VM, Janssen IMC, Hazebroek EJ, Hopman MTE. The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: a systematic review and meta-analysis. Obes Rev. 2022; 23(1): e13370.

[851] Voican CS, Lebrun A, Maitre S, et al. Predictive score of sarcopenia occurrence one year after bariatric surgery in severely obese patients. PLoS One. 2018; 13(5): e0197248.

[852] Law JM, Morris DE, Robinson L, et al. Reduced brown adipose tissue-associated skin temperature following cold stimulation in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2021; 22(3): 407-416.

[853] Faylon MP, Baumgard LH, Rhoads RP, Spurlock DM. Effects of acute heat stress on lipid metabolism of bovine primary adipocytes. J Dairy Sci. 2015; 98(12): 8732-8740.

[854] Shute R. Resistance exercise performed with a heated versus cooled muscle alters proteolytic gene response. Med Sci Sports Exercise. 2015; 47: 409.

[855] Ivanova YM, Blondin DP. Examining the benefits of cold exposure as a therapeutic strategy for obesity and type 2 diabetes. J Appl Physiol (1985). 2021; 130(5): 1448-1459.

[856] Zak RB, Shute RJ, Heesch MW, et al. Impact of hot and cold exposure on human skeletal muscle gene expression. Appl Physiol Nutr Metab. 2017; 42(3): 319-325.

[857] Berry DC, Jiang Y, Arpke RW, et al. Cellular aging contributes to failure of cold-induced beige adipocyte formation in old mice and humans. Cell Metab. 2017; 25(1): 166-181.

[858] Bhadada SV, Patel BM, Mehta AA, Goyal RK. β(3) receptors: role in cardiometabolic disorders. Ther Adv Endocrinol Metab. 2011; 2(2): 65-79.

[859] Vasconcelos J, Freire E, Almendra R, Silva GL, Santana P. The impact of winter cold weather on acute myocardial infarctions in Portugal. Environ Pollut. 2013; 183: 14-18.

[860] Calvani R, Picca A, Coelho-Júnior HJ, Tosato M, Marzetti E, Landi F. Diet for the prevention and management of sarcopenia. Metabolism. 2023; 146: 155637.

[861] Puppa MJ, Gao S, Narsale AA, Carson JA. Skeletal muscle glycoprotein 130’s role in Lewis lung carcinoma-induced cachexia. FASEB J. 2014; 28(2): 998-1009.

[862] Ruwanpura SM, McLeod L, Miller A, et al. Interleukin-6 promotes pulmonary emphysema associated with apoptosis in mice. Am J Respir Cell Mol Biol. 2011; 45(4): 720-730.

[863] Ruwanpura SM, McLeod L, Miller A, et al. Deregulated Stat3 signaling dissociates pulmonary inflammation from emphysema in gp130 mutant mice. Am J Physiol Lung Cell Mol Physiol. 2012; 302(7): L627-L639.

[864] Ando K, Takahashi F, Motojima S, et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol. 2013; 31(6): e69-e72.

[865] Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 2011; 11(12): 1663-1668.

[866] Miller A, McLeod L, Alhayyani S, et al. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma. Oncogene. 2017; 36(21): 3059-3066.

[867] Ando K, Takahashi F, Kato M, et al. Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer. PLoS One. 2014; 9(7): e102436.

[868] Angevin E, Tabernero J, Elez E, et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2014; 20(8): 2192-2204.

[869] Llovera M, Carbó N, García-Martínez C, et al. Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. Biochem Biophys Res Commun. 1996; 221(3): 653-655.

[870] Truyens C, Torrico F, Angelo-Barrios A, et al. The cachexia associated with Trypanosoma cruzi acute infection in mice is attenuated by anti-TNF-alpha, but not by anti-IL-6 or anti-IFN-gamma antibodies. Parasite Immunol. 1995; 17(11): 561-568.

[871] Shealy DJ, Wooley PH, Emmell E, et al. Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res. 2002; 4(5): R7.

[872] Llovera M, García-Martínez C, López-Soriano J, et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol. 1998; 142(1-2): 183-189.

[873] Miller LJ, Douglas C, McCullough FS, Stanworth SJ, Calder PC. Impact of enteral immunonutrition on infectious complications and immune and inflammatory markers in cancer patients undergoing chemotherapy: a systematic review of randomised controlled trials. Clin Nutr. 2022; 41(10): 2135-2146.

[874] Ma YJ, Yu J, Xiao J, Cao BW. The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: a systematic evaluation. Nutr Cancer. 2015; 67(1): 112-118.

[875] Pisters PW, Pearlstone DB. Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Crit Rev Clin Lab Sci. 1993; 30(3): 223-272.

[876] Hager K, Cudhea FP, Wong JB, et al. Association of National Expansion of Insurance Coverage of Medically Tailored Meals With Estimated Hospitalizations and Health Care Expenditures in the US. JAMA Netw Open. 2022; 5(10): e2236898.

[877] Berkowitz SA, Terranova J, Randall L, Cranston K, Waters DB, Hsu J. Association between receipt of a medically tailored meal program and health care use. JAMA Intern Med. 2019; 179(6): 786-793.

[878] Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO Guideline. J Clin Oncol. 2022; 40(22): 2491-2507.

[879] Madeddu C, Macciò A, Panzone F, Tanca FM, Mantovani G. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother. 2009; 10(8): 1359-1366.

[880] Brisbois TD, de Kock IH, Watanabe SM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011; 22(9): 2086-2093.

[881] Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D, et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018; 26(9): 3029-3038.

[882] Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999; 17(10): 3299-306.

[883] Yennurajalingam S, Williams JL, Chisholm G, Bruera E. Effects of dexamethasone and placebo on symptom clusters in advanced cancer patients: a preliminary report. Oncologist. 2016; 21(3): 384-390.

[884] Chasen M, Hirschman SZ, Bhargava R. Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J Am Med Dir Assoc. 2011; 12(1): 62-67.

[885] Malik JS, Yennurajalingam S. Prokinetics and ghrelin for the management of cancer cachexia syndrome. Ann Palliat Med. 2019; 8(1): 80-85.

[886] Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist. 2007; 12(5): 594-600.

[887] Takayama K, Katakami N, Yokoyama T, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer. 2016; 24(8): 3495-3505.

[888] Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016; 17(4): 519-531.

[889] Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol. 2017; 28(8): 1949-1956.

[890] Topyildiz F, Kiyici S, Gul Z, et al. Exenatide treatment causes suppression of serum ghrelin levels following mixed meal test in obese diabetic women. J Diabetes Res. 2016; 2016: 1309502.

[891] Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009; 54(10): 919-927.

[892] Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol. 2010; 56(16): 1310-1316.

[893] Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013; 34(7): 512-519.

[894] Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997; 96(2): 526-534.

[895] Jankowska EA, Rozentryt P, Ponikowska B, et al. Circulating estradiol and mortality in men with systolic chronic heart failure. Jama. 2009; 301(18): 1892-1901.

[896] Stewart Coats AJ, Ho GF, Prabhash K, et al. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016; 7(3): 355-365.

[897] Argilés JM, López-Soriano FJ, Stemmler B, Busquets S. Novel targeted therapies for cancer cachexia. Biochem J. 2017; 474(16): 2663-2678.

[898] Madeddu C, Dessì M, Panzone F, et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr. 2012; 31(2): 176-182.

[899] Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer. 2010; 18(8): 951-956.

[900] Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines(☆). ESMO Open. 2021; 6(3): 100092.

[901] Arends J, Baracos V, Bertz H, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017; 36(5): 1187-1196.

[902] Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021; 40(5): 2898-2913.

[903] Di Renzo L, Gualtieri P, Romano L, et al. Role of personalized nutrition in chronic-degenerative diseases. Nutrients. 2019; 11(8): 1707.

[904] Lee JLC, Leong LP, Lim SL. Nutrition intervention approaches to reduce malnutrition in oncology patients: a systematic review. Support Care Cancer. 2016; 24(1): 469-480.

[905] Macciò A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol. 2012; 124(3): 417-425.

[906] Solheim TS, Laird BJA, Balstad TR, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017; 8(5): 778-788.

[907] Avancini A, Trestini I, Tregnago D, et al. A multimodal approach to cancer-related cachexia: from theory to practice. Expert Rev Anticancer Ther. 2021; 21(8): 819-826.

[908] Nishikawa H, Goto M, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Cancer cachexia: its mechanism and clinical significance. Int J Mol Sci. 2021; 22(16): 8491.

[909] Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020; 21(4): 255-272.

[910] Sherpa C, Le Grice SFJ. Adeno-associated viral vector mediated expression of broadly-neutralizing antibodies against HIV-hitting a fast-moving target. Curr HIV Res. 2020; 18(2): 114-131.

[911] Hardcastle N, Boulis NM, Federici T. AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials. Expert Opin Biol Ther. 2018; 18(3): 293-307.

[912] Bulaklak K, Xiao B, Qiao C, et al. MicroRNA-206 downregulation improves therapeutic gene expression and motor function in mdx mice. Mol Ther Nucleic Acids. 2018; 12: 283-293.

[913] Lim CKW, Gapinske M, Brooks AK, et al. Treatment of a mouse model of ALS by in vivo base editing. Mol Ther. 2020; 28(4): 1177-1189.

[914] Nance ME, Shi R, Hakim CH, et al. AAV9 edits muscle stem cells in normal and dystrophic adult mice. Mol Ther. 2019; 27(9): 1568-1585.

[915] Zhang A, Li M, Wang B, Klein JD, Price SR, Wang XH. miRNA-23a/27a attenuates muscle atrophy and renal fibrosis through muscle-kidney crosstalk. J Cachexia Sarcopenia Muscle. 2018; 9(4): 755-770.

[916] Yue Y, Pan X, Hakim CH, et al. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet. 2015; 24(20): 5880-5890.

[917] Yamanaka S. Pluripotent stem cell-based cell therapy-promise and challenges. Cell Stem Cell. 2020; 27(4): 523-531.

[918] Rathod R, Surendran H, Battu R, Desai J, Pal R. Induced pluripotent stem cells (iPSC)-derived retinal cells in disease modeling and regenerative medicine. J Chem Neuroanat. 2019; 95: 81-88.

[919] Almada AE, Wagers AJ. Molecular circuitry of stem cell fate in skeletal muscle regeneration, ageing and disease. Nat Rev Mol Cell Biol. 2016; 17(5): 267-279.

[920] Collins CA, Olsen I, Zammit PS, et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell. 2005; 122(2): 289-301.

[921] Sacco A, Doyonnas R, Kraft P, Vitorovic S, Blau HM. Self-renewal and expansion of single transplanted muscle stem cells. Nature. 2008; 456(7221): 502-506.

[922] Tompkins BA, DiFede DL, Khan A, et al. Allogeneic mesenchymal stem cells ameliorate aging frailty: a phase ii randomized, double-blind, placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci. 2017; 72(11): 1513-1522.

[923] Buford TW. (Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease. Microbiome. 2017; 5(1): 80.

[924] Kang L, Li P, Wang D, Wang T, Hao D, Qu X. Alterations in intestinal microbiota diversity, composition, and function in patients with sarcopenia. Sci Rep. 2021; 11(1): 4628.

[925] Chen YM, Wei L, Chiu YS, et al. Lactobacillus plantarum TWK10 supplementation improves exercise performance and increases muscle mass in mice. Nutrients. 2016; 8(4): 205.

[926] Huang WC, Hsu YJ, Li H, et al. Effect of Lactobacillus Plantarum TWK10 on improving endurance performance in humans. Chin J Physiol. 2018; 61(3): 163-170.

[927] Toda K, Yamauchi Y, Tanaka A, et al. Heat-killed Bifidobacterium breve B-3 enhances muscle functions: possible involvement of increases in muscle mass and mitochondrial biogenesis. Nutrients. 2020; 12(1): 219.

[928] Varian BJ, Gourishetti S, Poutahidis T, et al. Beneficial bacteria inhibit cachexia. Oncotarget. 2016; 7(11): 11803-11816.

[929] Rizzoli R. Nutritional influence on bone: role of gut microbiota. Aging Clin Exp Res. 2019; 31(6): 743-751.

[930] van Dronkelaar C, van Velzen A, Abdelrazek M, van der Steen A, Weijs PJM, Tieland M. Minerals and sarcopenia; the role of calcium, iron, magnesium, phosphorus, potassium, selenium, sodium, and zinc on muscle mass, muscle strength, and physical performance in older adults: a systematic review. J Am Med Dir Assoc. 2018; 19(1): 6-11. e3.

[931] Chen LH, Huang SY, Huang KC, et al. Lactobacillus paracasei PS23 decelerated age-related muscle loss by ensuring mitochondrial function in SAMP8 mice. Aging (Albany NY). 2019; 11(2): 756-770.

[932] Bindels LB, Neyrinck AM, Claus SP, et al. Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia. ISME J. 2016; 10(6): 1456-1470.

[933] Nakamura S, Narimatsu H, Sato H, et al. Gene-environment interactions in obesity: implication for future applications in preventive medicine. J Hum Genet. 2016; 61(4): 317-322.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.